



 MICRORNA EXPRESSIONS IN THE MPTP-INDUCED PARKINSON’S 









A THESIS SUBMITTED FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
DEPARTMENT OF ANATOMY 
YONG LOO LIN SCHOOL OF MEDICINE 




































This thesis would not have been possible without the help of my supervisor 
Associate Professor Tay Sam Wah Samuel, Department of Anatomy, National 
University of Singapore. He has patiently guided me through my graduate 
studies offering invaluable guidance, constant encouragement in my scientific 
pursuits and the motivation to work hard and smart. He has been an 
inspirational role model and his values and principles will stay with me for a 
long time to come. I am honored to express my earnest thanks to him for being 
a wonderful mentor and I will always look up to his ideals and guidance.  
I am highly grateful and indebted to Associate Professor Thameem S 
Dheen, Department of Anatomy, National University of Singapore for his 
immense help and scientific critique throughout my course of study. His 
suggestions and ideas have helped me greatly in my research for which I am 
extremely grateful. His help has been indispensable in the completion of my 
thesis. 
I would like to express my sincere gratitude to Professor Bay Boon Huat, 
Head of the Department of Anatomy, who provided me an opportunity to 
work in this excellent research facility.  
I would like to appreciate Ms Ng Geok Lan, Ms.Yong Eng Siang and Ms 
Chan Yee Gek for their valuable assistance in the labs. I would also like to 
thank Mr Yick Tuck Yong, Ms Carolyne, Ms Violet Teo and Ms Diljit Kour, 
who have been of great help by providing their secretarial assistance.  
I must mention my labmates Mrs Meenalochani and Ms Ooi Yin Yin for 




thanks to all the staff and students in the Department of Anatomy for 
providing a friendly and cooperative working environment. 
I would like to thank Dr Makoto Yawata, Singapore Institute of Clinical 
Sciences for allowing me to use the laser capture microdissection equipment 
and providing all the help and guidance in carrying out the experiment. 
There are no words to thank my beloved parents Kanagaraj and Latha and 
my lovely sister Janani for being a constant source of encouragement and 
support. Without their love I wouldn’t have been where I am now. My uncle 
Raghavan and aunt Vellaithai are the ones who encouraged me to pursue my 
PhD and provided me with all the help and support to start off. It is my duty to 
thank them at this point. My in-laws have supported me immensely through 
the last year of my study and I must thank them for their patience and 
understanding. 
My husband, Selva Vijaya Kumar, has been my pillar of strength and 
without his love, constant motivation and understanding I am not sure I would 
have completed the writing of this thesis. 
All my friends in Singapore and India have been with me through my 
highs and lows and made all these years memorable and joyous. My heartfelt 
love and thanks to all of them. 
Last but not least, I thank God for all the good things and opportunities he 

















































Various portions of the present study have been presented, submitted for 
publication or under preparation for publication. 
Research articles 
 Nandhini Kanagaraj, He Beiping, S Thameem Dheen, Samuel, Sam 
Wah Tay. Downregulation of miR-124 in MPTP-treated mouse model 
of Parkinson’s disease and MPP+ treated MN9D cells modulates the 
expression of the calpain/cdk5 pathway proteins. (Under review in 
Neuroscience). 
 
 Nandhini Kanagaraj, Yawata M, He Beiping, S Thameem Dheen, 
Samuel, Sam Wah Tay. Dysregulated microRNA and mRNA networks 
in the substantia nigra of MPTP-treated mice. (Manuscript under 
preparation). 
 
 Nandhini Kanagaraj*, Yue Li*, S Thameem Dheen, Samuel, Sam 
Wah Tay. Stage and sub-field associated microRNA changes in 




 Nandhini Kanagaraj, S.T.Dheen, Z.F.Peng, D. Srinivasan, SSW Tay. 
MicroRNA-124 and its target genes are altered in the MPTP-induced 
Parkinson’s disease model. Experimental Biology 2012, San Diego, 
United States. 21-25 April 2012 (Oral presentation). 
Kanagaraj, N., Dheen, S. T., Peng, Z. F., Srinivasan, D. K., & Tay, S. 
S. W. (2012). MicroRNA-124 and its target gene are altered in the 
substantia nigra (SNc) of the brain of MPTP-mouse model of 
Parkinson's disease. The FASEB Journal, 26(1_MeetingAbstracts), 
83.86. 
 
 Nandhini Kanagaraj, S.T.Dheen, SSW Tay. miR-124 loss leads to 
upregulation of calpain/cdk5 pathway proteins in the Parkinson’s 
disease model in vitro and in vivo. SNA symposium 2013 (Best Oral 
presentation award). 
 
 Nandhini Kanagaraj, Yue Li, S Thameem Dheen, Sam Wah Samuel 
Tay. Stage and sub-Field associated microRNA changes in Epilepsy. 





Kanagaraj N, Li Y, Dheen ST, Tay SS (2013) Stage and Sub-Field 
associated microRNA changes in Epilepsy. The FASEB Journal 
27:533.537. 
 
 Nandhini Kanagaraj, S Thameem Dheen, Samuel Sam Wah Tay. 
MicroRNA-124 contributes to calpain-mediated cdk5 activation in the 
MPTP-induced Parkinson’s disease model. Neurodegenerative diseases 
meeting, Cold Spring Harbor Laboratories, New York, United States. 
28 November- 1 December 2012 (Poster presentation) 
 
 SSW Tay, Nandhini Kanagaraj. Role of miR-124 in dopaminergic 
neurons of MPTP-induced Parkinson’s disease model and in vitro. 2nd 
International Anatomical Sciences and Cell Biology Conference 
(IASCBC 2012), Chiang Mai, Thailand. 6-8 December 2012. 
 
 Nandhini Kanagaraj, S.T.Dheen, SSW Tay. Downregulation of miR-
124 in the MPTP-induced Parkinson’s disease mouse model and MPP+ 
treated MN9D cells modulates the expression of the calpain/cdk5 
pathway proteins. 3
rd
 YLLSOM Graduate Scientific Congress 2012. 
January 2013 (Poster presentation). 
 
 Nandhini Kanagaraj, Z.F.Peng, B.P. He, S.T.Dheen, SSW Tay. 
Altered expressions of microRNA-124 and its target CREB in the 
substantia nigra of MPTP-induced Parkinson’s disease model. 2nd 















                                       TABLE OF CONTENTS 
 
DECLARATION………………………………………………………………I 
ACKNOWLEDGEMENTS ............................................................................. III 
PUBLICATIONS ............................................................................................. VI 
SUMMARY .................................................................................................. XIX 
LIST OF TABLES ..................................................................................... XXIV 
LIST OF ILLUSTRATIONS/TEXT FIGURES ......................................... XXV 
ABBREVIATIONS ................................................................................... XXVI 
INTRODUCTION ............................................................................................. 1 
1.1 Parkinson’s disease ................................................................................. 2 
1.2 Epidemiology .......................................................................................... 3 
1.3 Clinical characteristics and diagnosis ..................................................... 5 
1.4 Neuropathological characteristics ........................................................... 6 
1.5 Etiology of PD ........................................................................................ 7 
1.5.1 Aging and PD ........................................................................................ 8 
1.5.2 Environmental factors ........................................................................... 8 
1.5.3 Genetic factors in PD .......................................................................... 11 
1.5.3.1 SNCA ........................................................................................... 11 
1.5.3.2 LRRK2 ......................................................................................... 12 




1.5.3.4 PINK1 .......................................................................................... 14 
1.5.3.5 PARK7 or DJ-1 ............................................................................ 15 
1.5.3.6 ATP13A2 ..................................................................................... 15 
1.5.3.7 Other genes with role in PD ......................................................... 15 
1.5.3.8 Risk factor genes .......................................................................... 16 
1.6 Mechanisms of cell death in PD ........................................................... 16 
1.6.1 Mitochondrial dysfunction ............................................................ 18 
1.6.2 Oxidative stress.............................................................................. 18 
1.6.3 Excitotoxicity................................................................................. 20 
1.6.4 Neuroinflammation ........................................................................ 20 
1.7 Animal models of Parkinson’s disease ................................................. 21 
1.7.1 MPTP model .................................................................................. 23 
1.8 Epigenetic mechanisms in PD .............................................................. 27 
1.8.1 DNA methylation ................................................................................ 28 
1.8.2 Histone modifications ......................................................................... 30 
1.8.3 MicroRNA .......................................................................................... 30 
1.9 Overview of microRNAs ...................................................................... 31 
1.9.1 Biogenesis of microRNAs .................................................................. 32 
1.9.1.1 miRNA genomics......................................................................... 32 
1.9.1.2 Transcription and processing ....................................................... 32 




1.9.2.1 Cleavage of target mRNA ............................................................ 36 
1.9.2.2 Deadenylation of mRNA ............................................................. 36 
1.9.2.3 Translational repression ............................................................... 37 
1.10 Principles of target recognition ............................................................. 38 
1.11 MicroRNAs in PD................................................................................. 38 
1.12 Aims of the present study ..................................................................... 43 
1.13.1 To investigate the degeneration of dopaminergic neurons in the 
SNc of MPTP-treated mice .......................................................................... 44 
1.13.2 To establish an in vitro model of PD using MN9D dopaminergic 
neuronal cell line .......................................................................................... 45 
1.13.3 To study miRNA expression changes in the SNc of MPTP-treated 
mice…… ...................................................................................................... 46 
1.13.4 To study the role of miR-124 in MPTP-induced dopaminergic 
neuronal death. ............................................................................................. 47 
1.13.5 To identify PD-associated target genes and pathways of the 
dysregulated miRNAs .................................................................................. 48 
MATERIALS AND METHODS ..................................................................... 49 
2.1 Animals ................................................................................................. 50 
2.2 MPTP treatment .................................................................................... 50 
2.2.1 Materials required ............................................................................. 50 
2.2.2 Injections ....................................................................................... 50 




2.3.1 Fresh brain samples for RNA isolation ......................................... 51 
2.3.2 Perfusion ........................................................................................ 51 
2.4 Isolation of the substantia nigra ............................................................ 52 
2.5 Cell culture ............................................................................................ 52 
2.5.1 Materials required .......................................................................... 52 
2.5.2 Cell culture maintenance ............................................................... 52 
2.6 MPP iodide treatment ........................................................................... 53 
2.6.1 Materials required .......................................................................... 53 
2.6.2 Cell differentiation ......................................................................... 53 
2.6.3 MPP+ treatment ............................................................................. 53 
2.7 Protein extraction .................................................................................. 54 
2.7.1 Materials required .......................................................................... 54 
2.7.2 Protein extraction ........................................................................... 54 
2.8 Estimation of protein concentration ...................................................... 54 
2.8.1 Materials required .......................................................................... 54 
2.8.2    Procedure ......................................................................................... 54 
2.9 Western Blotting ................................................................................... 55 
2.9.1 Materials Required ........................................................................ 55 
Equipment ................................................................................................ 55 
10% Resolving gel ................................................................................... 56 




6x SDS gel loading buffer........................................................................ 56 
10X Tris buffered saline (TBS) ............................................................... 56 
1X Tris buffered saline tween (TBST) .................................................... 57 
2.9.2 Procedure ....................................................................................... 58 
2.10 RNA isolation ....................................................................................... 58 
2.10.1 Materials required .......................................................................... 58 
2.10.2 Procedure ....................................................................................... 58 
2.10.2.1 RNA isolation from tissue samples............................................ 58 
2.10.2.2 RNA isolation from cells ........................................................... 59 
2.10.2.3 RNA isolation from Laser capture microdissected tissue .......... 59 
2.11 cDNA synthesis .................................................................................... 60 
2.11.1 Materials required ...................................................................... 60 
2.11.2 Procedure ................................................................................... 60 
2.12 Real time RT-PCR ................................................................................ 60 
2.12.1 Materials required ............................................................................. 60 
2.12.2 Procedure ................................................................................... 61 
2.13 cDNA synthesis for miRNA ................................................................. 61 
2.13.1 Materials required ......................................................................... 61 
2.13.2 Procedure ...................................................................................... 61 
2.14 microRNA PCR .................................................................................... 62 




2.14.2 Procedure ................................................................................... 62 
2.15 Cryosectioning ...................................................................................... 62 
2.16 Nissl staining (Cresyl-fast violet staining) ............................................ 63 
2.16.1 Materials required ...................................................................... 63 
2.16.2 Procedure ................................................................................... 63 
2.17 Immunofluorescence and immunohistochemistry studies .................... 63 
2.17.1 Materials required .......................................................................... 63 
2.17.2 Procedure ....................................................................................... 64 
2.17.2.1 Immunofluorescence in vivo ...................................................... 64 
2.17.2.2 Double immunofluorescence labeling in vivo............................ 65 
2.17.2.3 Immunohistochemistry .............................................................. 65 
2.17.2.4 Immunofluorescence in vitro ..................................................... 65 
2.18 In situ hybridization .............................................................................. 66 
2.18.1 Materials required ...................................................................... 66 
2.18.2 Procedure ................................................................................... 66 
2.19 Knockdown studies ............................................................................... 67 
2.19.1 Materials required ...................................................................... 67 
2.19.2 Procedure ................................................................................... 68 
2.20 Overexpression studies ......................................................................... 68 
2.20.1 Materials required ...................................................................... 68 




2.21 Extracellular ROS/RNS and H2O2 assay ............................................... 69 
2.22 Cell viability assay ................................................................................ 69 
2.23 Laser Capture Microdissection ............................................................. 70 
2.23.1 Materials required ...................................................................... 70 
2.23.2 Procedure ................................................................................... 70 
2.24 Staining for LCM .................................................................................. 71 
2.24.1 Materials required ...................................................................... 71 
2.24.2 Procedure ................................................................................... 71 
2.25 MicroRNA qPCR profiling ................................................................... 72 
2.25.1 Materials required ...................................................................... 72 
2.25.2 Procedure ................................................................................... 72 
2.26 Mouse Parkinson’s Disease PCR array................................................. 73 
2.26.1 Materials required .......................................................................... 73 
2.26.2 Procedure ........................................................................................... 73 
2.26.2.1 cDNA synthesis and preamplification ....................................... 73 
2.26.2.2 PCR array ................................................................................... 75 
2.26.2.3 Data analysis .............................................................................. 75 
2.27 IPA analysis of miRNA profiling data.................................................. 75 
2.28 Statistical analysis ................................................................................. 76 
RESULTS ........................................................................................................ 77 




3.1.1 Neuronal loss ................................................................................. 78 
3.1.1.1 Nissl staining ................................................................................ 78 
3.1.1.2 Tyrosine hydroxylase immunostaining ........................................ 78 
3.1.2 Tyrosine hydroxylase and dopamine transporter gene expression 
changes.. ....................................................................................................... 79 
3.1.3 Proinflammatory cytokines in the SNc of MPTP-treated animals 79 
3.1.4 Inducible nitric oxide synthase (iNOS) expression ....................... 80 
3.2 MN9D dopaminergic cells .................................................................... 80 
3.3 Laser capture microdissection............................................................... 81 
3.4 MicroRNA qPCR profiling ................................................................... 81 
3.5 qPCR analysis of specific miRNAs in the SNc of MPTP-treated mice 81 
3.5.1 miR-204-5p expression.................................................................. 82 
3.5.2 Expression of miR-129-3p............................................................. 82 
3.5.3 Expression pattern of miR-342-3p ................................................ 82 
3.5.4 miR-9-5p expression...................................................................... 83 
3.5.5 miR-125b-5p expression................................................................ 83 
3.5.6 Expression of miR-128-3p............................................................. 83 
3.5.7 Expression pattern of miR-24-3p .................................................. 83 
3.5.8 miR-30b and miR-30c ................................................................... 83 




3.6.1 miR-124 expression in the MPTP-lesioned mice and MPP+ treated 
MN9D cells .................................................................................................. 84 
3.6.2 Calpains 1 and 2- predicted targets of miR-124 ................................ 85 
3.6.3 Calpain 1 and calpain 2 expression in MPTP-treated mouse SNc .... 85 
3.6.4 Transfection of miR-124-inhibitor .................................................... 85 
3.6.5 Expression of calpain 1 and calpain 2 in MPP iodide-treated and 
miR-124 knockdown MN9D cells ................................................................... 86 
3.6.6 Expression of p35 and p25 increased on MPP iodide treatment and 
miR-124 knockdown ........................................................................................ 86 
3.6.7 Increased cdk5 expression ................................................................. 87 
3.6.8 Calpain 1 expression increased significantly after miR-124 target 
protector transfection ....................................................................................... 87 
3.6.9 Studies on overexpression of miR-124 in MN9D cells..................... 88 
3.6.10 ROS/RNS and H2O2 production and MN9D cell viability after 
knockdown or overexpression of miR-124 ...................................................... 88 
3.7 miRNA target prediction....................................................................... 89 
3.7.1 Parkinson’s disease PCR array ...................................................... 89 
3.7.2 PD-specific target mRNAs of the deregulated miRNAs ............... 90 
3.7.3 Targets of upregulated miRNAs .................................................... 90 
3.7.4 Targets of downregulated miRNAs ............................................... 91 
DISCUSSION .................................................................................................. 92 




4.2 MPTP induces TH and DAT gene expression changes ........................ 94 
4.3 Proinflammatory genes are upregulated in the SNc of MPTP-treated 
mice… .............................................................................................................. 95 
4.4 MN9D cell line as a model for PD in vitro ........................................... 97 
4.5 Laser capture microdissection helps efficiently isolate the SNc region97 
4.6 miRNA expression is modulated in the SNc upon MPTP treatment .... 98 
4.7 miRNA expressions change with time after MPTP-treatment. ............ 99 
4.8 Effect of miR-124 down-regulation in the dopaminergic neurons ..... 103 
4.9 Pathways and genes modulated by upregulated miRNAs .................. 107 
4.9.1 Dopamine signaling pathway ...................................................... 107 
4.9.2 miRNAs targeting LRRK2 .......................................................... 110 
4.9.3 α-synuclein and miRNAs ............................................................ 111 
4.9.4 GABAB receptor 2 and miRNAs ................................................. 112 
4.10 Pathways and genes modulated by the downregulated miRNAs........ 113 
4.10.1 Mitochondrial dysfunction .......................................................... 114 
4.10.2 Protein ubiquitination .................................................................. 115 
CONCLUSIONS AND FUTURE DIRECTIONS......................................... 117 
REFERENCES .............................................................................................. 123 









































Parkinson’s disease (PD) is the second most common neurodegenerative 
disease, after Alzheimer’s disease, which primarily affects the elderly. PD is a 
result of the loss of dopaminergic neurons in the substantia nigra pars 
compacta (SNc) which is also accompanied by the formation of aggregates of 
α-synuclein called Lewy bodies. The major symptoms of PD are associated 
with motor function which includes tremor, rigidity, postural instability and 
bradykinesia. Being a complex disorder caused by a combination of genetic 
and environmental factors, developing therapeutics which can cure PD has 
remained elusive. The existing treatment options only provide symptomatic 
relief and cause severe side effects on long term use. Hence, an enhanced 
understanding of the molecular mechanisms involved in the pathogenesis of 
PD can aid in the development of better treatment options to cure the disease.  
The degeneration of the SNc dopaminergic neurons induced by 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been well documented and 
widely used to model PD in animals. Several processes involved in human PD 
pathogenesis are found to be altered in the MPTP-induced PD models. 
However, the mechanisms involved in the dopaminergic neuronal 
degeneration are not completely understood.  
The foremost aim of the present study was to establish an acute MPTP-
induced PD mouse model. The loss of dopaminergic neurons and changes in 
gene expression of tyrosine hydroxylase (TH) and dopamine transporter 
(DAT), both important genes in the dopamine synthesis and uptake 
mechanism were analysed in the SNc of MPTP-induced PD mice as compared 
to controls. Time-dependent reduction in the number of dopaminergic neurons 




points after MPTP treatment. Since PD involves a complex interplay of 
several pathogenic processes, the expression of proinflammatory genes, 
tumour necrosis factor-α (TNFα) and interleukin-1β (IL1β) were assessed at 
different time points to demonstrate the role of inflammation in the acute 
MPTP-model of PD. An increased expression of both the genes during the 
first few days after MPTP treatment which gradually decreases with time 
provides evidence for the role of inflammation in the MPTP-induced 
dopaminergic neuronal death. Increased nitric oxide (NO) has been shown to 
induce cell death and the increased expression of the inducible nitric oxide 
synthase (iNOS) and its colocalization with TH-immunopositive neurons at 
early time points after MPTP treatment suggests that the iNOS enzyme plays 
an important role in initiating the degeneration of dopaminergic neurons. 
MicroRNAs (miRNAs) are small, non-coding RNAs known to play important 
regulatory roles in several cellular processes. The role of miRNAs in the 
maintenance of normal cellular functions and in disease-inducing pathways 
has been increasingly demonstrated. Owing to the difficulty in obtaining 
human PD brain tissues and the variations in the time of obtaining the PD 
tissues, there have been very few studies on the involvement of miRNAs in 
PD. A detailed analysis of miRNA expression changes in the MPTP-model 
could thus provide insights into similar miRNA changes occurring in human 
PD. Hence, the next aim was to identify miRNA expression changes in the 
SNc of MPTP-induced mice (sacrificed on day 5 after MPTP treatment) 
isolated by laser capture microdissection (LCM) as compared to the control 
mice. Expression profiling by qPCR revealed differential expression of 74 




upregulated and 38 were downregulated. Analyzing the expression of a few of 
these miRNAs in the SNc of MPTP-treated and control mice at different time 
points after MPTP treatment, it was observed that the expression levels varied 
at different time points. This indicates that MPTP induces time-dependent 
expression changes in miRNAs thereby suggesting a role for miRNAs in the 
degenerative process. 
Among the differentially expressed miRNAs, miR-124 (a brain-abundant 
miRNA) was found to be downregulated from the profiling data. Analysis of 
miR-124 expression at different time points indicated a time-dependent 
downregulation of expression which was evident from 24h after MPTP 
treatment. The miR-124 is predicted to target the calpains 1 and 2 which are 
known to play a role in the neuronal death in human PD and MPTP-induced 
PD models by altering the expression and activity of cyclin-dependent kinase 
5 (cdk5). The expression of calpains 1 and 2 was found to be increased in the 
SNc of MPTP-induced mice and MPP iodide-treated MN9D dopaminergic 
neuronal cells. Loss of function studies by transfecting MN9D cells with miR-
124 inhibitors showed that miR-124 contributes to the increased expression of 
calpain 1, p35/p25 and cdk5 along with a marginal increase in reactive oxygen 
and nitrogen species (ROS/RNS) and hydrogen peroxide (H2O2) while also 
compromising the viability of the cells. Gain of function analysis was 
performed using miR-124 mimics. miR-124 overexpression in MPP iodide- 
treated MN9D cells was capable of attenuating the expression of calpain 1, 
p35/p25 and cdk5 accompanied by reduced neuronal death. Calpain 1 target 




mRNA. Taken together, these results suggest an important role for miR-124 in 
the survival of dopaminergic neurons in the MPTP-induced PD model. 
In order to analyze the significance of the miRNA expression changes in the 
MPTP-induced PD model, a PD-specific PCR array of 84 genes known to play 
a role in PD pathogenesis was performed. The miRNA and mRNA profiles 
were analyzed to identify miRNA targets among the differentially expressed 
PD-specific mRNAs. The analysis revealed that several of the differentially 
expressed mRNAs were targets of the dysregulated miRNAs. The miRNAs 
and target mRNAs were mainly involved in dopamine signaling, 
mitochondrial dysfunction and protein ubiquitination pathways. Further, genes 
like α-synuclein (SNCA), leucine-rich repeat kinase 2 (LRRK2), PTEN-
induced kinase 1 (PINK1) and PARK7 which are known to play prominent 
roles in PD pathogenesis are targeted by the dysregulated miRNAs identified 
by the miRNA profiling.  
Hence, the results of the present study show that miRNA expression levels in 
the SNc are altered as a result of MPTP treatment. The dysregulated miRNAs 
target several important genes shown to be involved in the pathogenesis of PD 
and modulate pathways shown to be altered in PD. However, detailed analysis 
of individual miRNAs and their targets is essential to elucidate the exact role 
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1.1 Parkinson’s disease 
Parkinson’s disease (PD) is an incapacitating neurodegenerative disorder 
characterized by severe motor symptoms like tremor, muscle rigidity, paucity 
of voluntary movements and postural instability (Lang and Lozano, 1998). 
Parkinson’s disease which is the leading cause of Parkinsonism (a generic 
term describing clinical conditions which result in tremor, rigidity, postural 
instability and bradykinesia) was first described by James Parkinson in his 
publication “An essay on the shaking palsy” in 1817 (Parkinson, 2002). Since 
the pioneering essay, a number of clinicians and researchers have analyzed the 
various clinical and pathological aspects of PD identifying several genetic and 
environmental factors playing a role in PD. However, there is no single cause 
identified as yet. Age is the only most consistent risk factor (Lang and Lozano, 
1998, Collier et al., 2011) and owing to the multifactorial etiology, there is a 
dearth of treatment options which can cure or halt the progression of PD.  
 Levodopa, discovered in 1961 (Birkmayer and Hornykiewicz, 1998) 
remains the most effective treatment for PD to date. However, its action is 
limited to symptomatic relief. Treating PD by surgical ablative procedures like 
pallidotomy (Lang et al., 1997, Munro-Davies et al., 1999, Intemann et al., 
2001, Vitek et al., 2003), thalamotomy (Moriyama et al., 1999, Duval et al., 
2006) , and subthalamotomy (Alvarez et al., 2001, Patel et al., 2003) have 
been in practice, but they are rarely used in recent times owing to the severe 
side-effects (Walter and Vitek, 2004). Deep brain stimulation (DBS) of the 
internal globus pallidus, subthalamic nucleus, and thalamus has also been 
shown to significantly improve the motor symptoms associated with PD 




Parkinson's Disease Study, 2001, Pierantozzi et al., 2002, Cozzens, 2007, 
Nazzaro et al., 2012). Yet, surgical methods are expensive and effective only 
in a relatively limited number of patients based on various criteria like their 
responsiveness to anti-Parkinsonian drugs, age, symptoms and the extent of 
disease progression.  
In recent years, it has become increasingly evident that PD also 
induces several non-motor symptoms apart from the classic motor symptoms 
defining the disease. These non-motor symptoms seldom respond to PD drug 
or surgical therapies leading to disability and diminished quality of life for the 
patients. PD, as of today is a brain disorder affecting more than the motor 
system and calls for treatment options that reach beyond the traditional motor-
function improving therapy.  The search for uncovering the underlying 
mechanisms which can aid the development of alternative treatment options 
and biomarkers for PD has become an active interest of scientists worldwide. 
 
1.2 Epidemiology 
The actual number of PD patients in the world is hardly known. This 
may be attributed to the fact that many patients are undiagnosed or 
misdiagnosed, due to the subtle nature of symptoms during the onset of the 
disease, in addition to the lack of large-scale studies on the disease 
epidemiology (Wirdefeldt et al., 2011). PD is the second most common 
neurodegenerative disease after Alzheimers’s disease and an estimated seven 
to ten million people worldwide are living with PD (Tanner and Goldman, 
1996). With increase in life expectancy, these numbers are likely to rise 




between 31 and 970 per 100,000 people based on registry-based studies with 
the numbers being higher when the criterion was limited to over 65 years of 
age (Wirdefeldt et al., 2011). A study based on the projected population of the 
five largest countries in Europe and the ten most populous countries in the 
world has estimated the number of PD patients to grow from 4.1 million in 
2005 to between 8.7 and 9.3 million in 2030 (Dorsey et al., 2007).  
The corresponding lifetime risk of PD is estimated to be 2% in men 
while it is lower in women, being 1.3% (Elbaz et al., 2002). The incidence 
rates reported by studies accounting for all age groups ranged from 1.5 and 22 
per 100,000 person-years. This rate, however, is higher when considering only 
populations above the age of 60 (Wirdefeldt et al., 2011).  Asia and Africa 
have been reported to have a lower prevalence of PD compared to other parts 
of the world (Van Den Eeden et al., 2003). However, the variations could be 
caused by the lack of detailed observations, shorter life expectancy and other 
socioeconomic factors. Around 25-40% of PD patients eventually develop 
dementia (as the degeneration spreads to the cortex and limbic regions of the 
brain) which is a major contributor to the reduced life expectancy and life 
quality associated with the disease (de Lau and Breteler, 2006). Being mostly 
an age-associated disease, PD has its onset in people above the age of 50 
classified as sporadic or idiopathic PD, however 5-10% of patients have the 






1.3 Clinical characteristics and diagnosis 
The cardinal defining features of PD are resting tremor, rigidity and 
akinesia or bradykinesia (Lang and Lozano, 1998). Resting tremor of 4-6Hz is 
one of the initial symptoms in 70% of PD patients. It generally worsens as the 
disease progresses. Rigidity and bradykinesia, however, develop progressively 
during the disease. Postural instability is another important symptom though it 
is not specific and might not be present in young onset PD patients. The 
instability gradually leads to poor balance and slowness of gait along with 
freezing (Samii et al., 2004). The non-motor symptoms of PD include 
cognitive disabilities, autonomic dysfunctions, sensory system defects and 
sleep disorders (Chaudhuri et al., 2011).  
The diagnosis is based on the clinical criteria and owing to the fact that 
Parkinsonism can arise due to different causes like drugs, environmental 
factors and other diseases, misdiagnosis and underdiagnosis of PD are 
common. The best way to identify PD is by a neuropathological examination. 
With improved medical facilities and more rigorous diagnostic criteria, 
efficiently distinguishing PD from other causes of Parkinsonism can be 
achieved.  A good response to Levodopa also differentiates PD from other 
Parkinsonian disorders. A proper diagnosis is achieved through careful 
examination of the patient’s medical history and systematic monitoring of the 





1.4 Neuropathological characteristics 
The most distinct pathological features of PD are the selective loss of 
dopaminergic neurons and the occurrence of Lewy bodies (LBs) and Lewy 
neurites (LNs) (Bethlem and Jager, 1960, Braak and Braak, 2000).  
1.4.1 Loss of dopaminergic neurons 
The neuronal loss is significantly higher (60-70%) in the ventrolateral 
tier of the substantia nigra pars compacta (SNc) compared to the other regions. 
This pattern is a characteristic feature that distinguishes PD from the neuronal 
loss occurring due to aging and other degenerative diseases (Fearnley and 
Lees, 1991). The dopaminergic neurons present in the ventral tegmental area 
(VTA) adjacent to the SNc are significantly less affected in PD and the 
dopamine levels in the main region of projection of the VTA neurons 
(amygdala) are more compared to the dorsolateral putamen to which the SNc 
neurons project. By the time the symptoms of PD become visible, almost 60% 
of the dopaminergic neurons in the SNc are already lost and 80% of the 
dopamine depleted in the putamen (Dauer and Przedborski, 2003). This 
reduction in dopamine is the main cause of the rigidity and bradykinesia 
associated with PD. Dopamine transporter (DAT) is an essential determinant 
of extracellular dopamine concentrations and apart from the loss of neurons 
expressing DAT there is also a down-regulation in the expression of DAT in 
order to compensate for the dopamine loss by prolonging the extracellular 
half-life of dopamine (Uhl et al., 1994). 
1.4.2 Lewy bodies and Lewy neurites 
Lewy bodies are eosinophilic hyaline intraneuronal inclusions, first 




dorsal motor nucleus of the vagus in paralysis agitans patients (Lewy, 1912). 
Later, they were also identified in the substantia nigra and have since been 
hallmarks of idiopathic PD (Gibb and Lees, 1989). These intracytoplasmic 
inclusions are composed mainly of α-synuclein, neurofilament proteins and 
ubiquitin (Goldman et al., 1983, Spillantini et al., 1998). Mutated forms of α-
synuclein being discovered in families linking it to PD were a major discovery 
in the genetics of PD; however, the presence of the protein in Lewy bodies has 
also asserted its role in the sporadic form of the disease. The deposition of 
aggregated α-synuclein in the cytoplasm and neurites is a major pathological 
sign in PD. Apart from α-synuclein, neurofilament proteins, major 
components of the neuronal cytoskeleton, and ubiquitin (a heat shock protein 
involved in targeting damaged and unwanted proteins towards degradation) 
are found in abundance in the Lewy bodies. They occur both in the brainstem 
and cortices of PD patients and are thought to be present even at early 
presymptomatic stages of PD (Dickson et al., 2008). Apart from the 
intracytoplasmic aggregates, these protein inclusions also lead to swollen, 
degenerating neuronal processes or neurites called as Lewy neurites (Braak et 
al., 1999) . The Lewy body pathology in the brain becomes widespread in the 
brain with age in PD patients. 
 
1.5 Etiology of PD 
The etiology of PD has remained shrouded and elusive by large. In 
spite of concentrated efforts towards identifying the causes of PD, there is no 




multifactorial disease with several causative factors and many more being 
added with research advances.  
1.5.1 Aging and PD 
Age is the most crucial factor with regards to PD development. Based 
on epidemiological studies, the incidence of PD increases with age and peaks 
around 80 years (Van Den Eeden et al., 2003). Irrespective of the genetic-
influence, PD is known to worsen with age. The brain utilizes 20% of the total 
oxygen used by the body even at rest generating abundant reactive oxygen 
species, and being low in antioxidants compared to other body parts, is prone 
to oxidative stress. The oxidative damage in the brain increases with age 
(Harman, 1992, Kumar et al., 2012). Aging also induces a low-level chronic 
inflammation in the brain leading to increased production of proinflammatory 
cytokines by the glial cells (Franceschi et al., 2007, Chung et al., 2009). 
Combined together, these activities lead to neuronal death in the brain. In 
addition to these naturally occurring mechanisms, environmental and genetic 
factors augment the processes leading to neuronal death in PD.  
1.5.2 Environmental factors 
The implication of environmental factors in PD has been studied 
extensively over the decades. Living in rural areas, well water consumption 
and exposure to pesticides and herbicides have been well-associated with PD 
development (Semchuk et al., 1992). Though they do not point towards 
causality, these environmental factors have been shown to play a role in PD. 
Studies showing these factors being involved in both young and late onset 
forms of PD reinforced their importance in the disease. The accidental 




(MPTP) to induce selective dopaminergic neuronal death initiated an interest 
in the potential environmental toxins that are capable of causing PD (Langston 
and Ballard, 1983). Since then, several other compounds contributing to 
neurodegeneration similar to PD have been identified and studied. 
Tetrahydroisoquinoline (TIQ) and β-carboline (β-C) derivatives are naturally 
occurring compounds similar to MPTP in structure and mechanism of action 
(interference with mitochondrial respiration) in inducing Parkinsonian 
symptoms in non-human primates (Nagatsu and Yoshida, 1988, Suzuki et al., 
1990, Matsubara et al., 1998). Further, these compounds have been identified 
in the cerebrospinal fluid of PD patients (Kotake et al., 1995, Matsubara et al., 
1995). Nevertheless, these compounds are less potent than MPTP and might 
not reach the necessary toxic levels on natural exposure. This fact demands the 
need for more detailed studies to prove their place in PD pathogenesis. They 
might however, be postulated to play synergistic roles with other factors that 
lead up to neurodegeneration in the long run.   
Pesticide exposure is another known factor in the complex etiology of 
PD. Paraquat, a widely used herbicide, is known to cross the blood-brain 
barrier and induce nigrostriatal damage (Sanchez-Ramos et al., 1987, Liou et 
al., 1997). It has also been shown to have added toxicity to dopaminergic 
neurons when acting with the fungicide manganese 
ethylenebisdithiocarbamate (maneb) (Thiruchelvam et al., 2000). 
Organochlorine, organophosphate and rotenoid derivatives are additional 
classes of compounds associated with PD (Fleming et al., 1994, Corrigan et 
al., 1998, Bhatt et al., 1999, Muller-Vahl et al., 1999). Rotenone acts by 




2012) . Among these compounds, paraquat and rotenone are used to model PD 
in experimental animals owing to their similarities in pathogenic mechanisms 
with human PD. Apart from chemical compounds, exposure to metals has also 
been linked to PD. Manganese has been known to result in parkinsonian 
symptoms but the symptoms do not respond to L-DOPA treatment and the 
target region of the metal is the globus pallidus rather than the nigrostriatal 
system (Pal et al., 1999). Iron accumulation in the brain of PD patients has 
been reported and combined with the down-regulation of ferritin (the protein 
involved in binding to iron to maintain its non-reactive state) could probably 
lead to oxidative stress and neurodegeneration (Lan and Jiang, 1997, 
Mochizuki and Yasuda, 2012). The combined exposure of metals like lead, 
copper and iron could pose an increased risk of neuronal death but the effect 
of prolonged exposure and accumulation of metals in PD requires further 
extensive study. Tobacco and caffeine are two compounds known to decrease 
the risk of PD unlike the other environmental components discussed above 
(Gorell et al., 1999, Ross et al., 2000). Tobacco mediated neuroprotection has 
been attributed to two major factors; i) nicotine itself is neuroprotective as 
postulated by a few studies, ii) nicotine can reduce monoamine oxidase 
activity and thereby reducing dopamine turnover (Court et al., 1998, Quik et 
al., 2012). Caffeine being an adenosine receptor antagonist may remove 
inhibition of adenosine and promote dopaminergic neurotransmission 
(Svenningsson and Fredholm, 1997). However, both these compounds need to 
be studied epidemiologically and experimentally to confirm their actual roles 




1.5.3 Genetic factors in PD 
Familial cases of PD are rare and account for only 10% of the total PD 
patients (Thomas and Beal, 2007). However, over the years, several PD-
related genes have been discovered. A critical factor in determining the nature 
of PD is the age of onset of the disease, the younger the age of onset the more 
likelihood that genetic factors play a role in the etiology.  
There have been 18 identified chromosomal regions linked to PD, 
named Park and suffixed with numbers in order of their identification. There 
are six genes related to PD unequivocally; mutated forms of α- synuclein (non 
A4 component of amyloid precursor) (SNCA) and Leucine-rich repeat kinase 
2 (LRRK2) are known to cause autosomal-dominant forms of PD; and Parkin, 
phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1), 
Parkinson protein 7 (Park7) or DJ-1and ATPase Type 13A2 (ATP13A2), 
mutations which can cause autosomal recessive forms of PD.  Apart from 
these genes causing monogenic forms of PD, there are several other known 
genes which can be causative agents of PD, these are ubiquitin c-terminal 
hydrolase (UCHL1), grb10 interacting gyf protein 2 (GIGYF2), htra serine 
peptidase 2 (OMI/HTRA2), phospholipase a2, group VI (cytosolic, calcium-
independent) (PLA2G6) and F-box protein 7 (FBXO7). However, the link of 
some of these genes to PD is not confirmed or occurs very rarely. 
1.5.3.1 SNCA 
SNCA was the first identified gene with mutations reported to cause 
PD (Polymeropoulos et al., 1997). Mutated SNCA can lead to early onset PD 
which initially responds well to Levodopa treatment but rapidly progresses 




cognitive abilities (Ross et al., 2008). SNCA encodes an abundant cytosolic 
protein, α-synuclein (140 amino acids). Wild-type α-synuclein is translocated 
to lysosomes for degradation aided by the lysosomal enzyme β-
glucocerebrosidase (Cuervo et al., 2004, Manning-Boğ et al., 2009) . 
Mutations in β-glucocerebrosidase are now known to be a risk factor for PD 
development owing to its relation with α-synuclein (Nichols et al., 2009, 
Sunwoo et al., 2011). Malfunctioning of this protein can lead to the 
accumulation of α-synuclein which forms a positive feedback loop with β-
glucocerebrosidase (Mazzulli et al., 2011, Yap et al., 2011).  Missense 
mutations, duplications and triplications of the SNCA gene have been reported 
from the studies on families with PD. With increased copy numbers of the 
SNCA gene, there is earlier onset of PD, rapid disease progression and more 
severe symptoms (Ross et al., 2008). However, these mutated forms of SNCA 
as causes for PD are a rare occurrence. 
Accumulation of α-synuclein in Lewy bodies and Lewy neurites is also 
found in idiopathic PD indicating a role for the SNCA gene in both familial 
and sporadic PD (Cookson, 2005).  
1.5.3.2 LRRK2 
Unlike SNCA, LRRK2 mutations cause mid-to-late-onset PD which 
progresses slowly. Dementia is not common and the symptoms respond well 
to Levodopa. Lewy bodies, however, do not occur in all cases. LRRK2 
mutations are also linked to many sporadic PD cases. Mutations in LRRK2 are 
the most common genetic cause for PD amounting to about 4% of familial PD 
and 1% of sporadic PD (Healy et al., 2008). The LRRK2 gene codes for the 




than 50 mutations have been reported in the LRRK2 gene from which 16 are 
known to be pathogenic (Nuytemans et al., 2010). The exact mechanism by 
which LRRK2 mutations lead to PD is still uncertain. Owing to the large size 
of the protein, changes in specific domains might lead to modifications in the 
interaction of the protein with other factors leading to the pathogenic 
processes (Cookson, 2012). Mutations can also alter the kinase activity of the 
protein affecting the downstream interactions (Greggio, 2012). It is known to 
affect the phosphorylation of several proteins in the MAPK pathway. LRRK2 
also interacts with the E3 ubiquitin ligase, Parkin. However, further 
investigations are needed to analyze the actual underlying process leading to 
LRRK2 mediated pathogenic activities in PD. 
1.5.3.3 Parkin 
Parkin was the second PD gene identified and causes the autosomal recessive 
form of the disease. Mutations in parkin lead to the early onset form of PD 
which responds well to Levodopa treatment. However, homozygous mutations 
in parkin are the leading cause of juvenile PD with age of onset at or below 21 
years (Kitada et al., 1998, Lücking et al., 2000). Parkin mutations account for 
around 77% of familial PD cases with age of onset less than 30 years and 
about 10-20% of the total early onset cases (Klein and Lohmann-Hedrich, 
2007). The mutations discovered in parkin are numerous and span all domains 
of the gene.  Coding for a 465 amino acid protein, which functions as an E3 
ubiquitin ligase in the process of ubiquitination and plays a role in receptor 
trafficking, mutations in the parkin gene can lead dysfunction of the ubiquitin-
proteasome system and accumulation of toxic substrates. Parkin associates 




transcription of mtDNA-encoded respiratory chain complexes. Hence, 
mutations in Parkin could directly affect the respiratory process in 
mitochondria. The protein also activates the IkappaB kinase/nuclear factor-
kappaB signaling pathway which mediates its neuroprotective activity. 
Mutations in Parkin do not stimulate this pathway. It is also known to play a 
role in the phosphatidylinositol 3-kinase/Akt cell survival signaling which is 
lost when the protein is mutated. Parkin also plays a role in sporadic PD where 
it is inactivated by oxidative and nitrosative stress (Yao et al., 2004, Meng et 
al., 2011) and tyrosine phosphorylation (Imam et al., 2011). This leads to the 
accumulation of the substrates of Parkin protein in the cells and consequently 
cell death (Giasson and Lee, 2001). 
1.5.3.4 PINK1 
PINK1 mutations were identified in some families with early onset PD 
(Valente et al., 2004, Bonifati et al., 2005). Most PINK1 mutations are 
missense or nonsense mutations with very few deletions reported. PINK1 gene 
codes for a 581 amino acid ubiquitously expressed protein kinase. Most 
mutations in the gene are kinase domain-affecting loss-of-function mutations, 
illustrating the importance of the kinase activity of the protein (Song et al., 
2013). No putative substrates to the kinase have been identified till date. 
PINK1 works upstream of parkin in the cells to aid in the autophagy of 
damaged mitochondria (Morais et al., 2009, Geisler et al., 2010, Narendra et 
al., 2012). The loss of this activity leads to accumulation of the damaged 




1.5.3.5 PARK7 or DJ-1  
DJ-1 mutations cause the autosomal recessive form of PD, though only 
a few cases have been reported (1-2% of early onset PD cases) (Abou-Sleiman 
et al., 2003, Pankratz et al., 2006). DJ-1 codes for a 189 amino acid protein 
which is expressed ubiquitously. The protein functions as a sensor for 
oxidative stress in cells and plays a neuroprotective and antioxidant role in 
neurons (Canet-Aviles et al., 2004). However, mutations in the gene lead to 
the formation of a misfolded or unstable protein which lacks the 
neuroprotective ability (Malgieri and Eliezer, 2008, Ariga et al., 2013).  
1.5.3.6 ATP13A2 
Mutations in the ATP13A2 gene cause a severe form of the autosomal 
recessive PD called Kufor-Rakeb syndrome (KRS) with pyramidal 
degeneration, dementia and rapid disease progression (Williams et al., 2005, 
Ramirez et al., 2006). It is a large gene coding for an 1180 amino acid protein 
whose physiological function is not yet clear. However, it is predicted to play 
a role in lysosomal function and hence the mutations affecting its function lead 
to reduced lysosomal activity mediating cell death (Park et al., 2011, Usenovic 
et al., 2012). The expression of ATP13A2 protein is also found to be 
decreased in sporadic PD patients (Murphy et al., 2013). 
1.5.3.7 Other genes with role in PD 
There are several other genes known to play a role in familial PD 
which include UCHL-1 (Liu et al., 2002), GYGYF2 (Lautier et al., 2008), 
OMI/HTRA2 (Strauss et al., 2005), PLA2G6 (Tan et al., 2010, Lu et al., 2012) 
and FBXO7 (Di Fonzo et al., 2009) (Paisán-Ruiz et al., 2010).  However, the 




cases resulting from these mutations are extremely rare (Klein and 
Westenberger, 2012).  
1.5.3.8 Risk factor genes 
Apart from genes which are causative, there are also several genes 
which are known to increase the risk of PD on being mutated. PARK16, GAK, 
Microtubule-Associated Protein Tau (MAPT), Glucosidase, Beta, Acid 
(GBA), N-acetyltransferase 2 (NAT2), inducible nitric oxide synthase 2a 
(INOS2A), Major Histocompatibility Complex, Class II, DR Alpha (HLA-
DRA), and Apolipoprotein E (ApoE) are a few known examples (Klein and 
Westenberger, 2012).  
The genetic form of PD is rare compared to its sporadic counterpart; however 
a detailed understanding of the genetic factors will equip us better in 
perceiving the pathogenic mechanisms involved in idiopathic PD. This 
knowledge can also lead scientists towards the development of cause-directed 
therapeutic strategies. 
 
1.6 Mechanisms of cell death in PD 
The pathogenic mechanisms underlying the dopaminergic neuronal 
death have been studied extensively. The results of these investigations have 
pointed to the fact that several mechanisms act in synergy contributing to the 
cell loss. Among these, mitochondrial dysfunction, oxidative stress, protein 
accumulation, defects in the ubiquitin-proteasome pathway, excitotoxicity, 
neuroinflammation, iron accumulation and autophagy are a few that have been 
studied comprehensively (Levy et al., 2009). The PD pathway including the 





Fig I: Biological processes and genes implicated in PD. 







1.6.1 Mitochondrial dysfunction  
Mitochondrial dysfunction is one of the important causes of neuronal 
death in PD (Perier et al., 2012, Perier and Vila, 2012). The dysfunction of 
mitochondria can lead to depletion of ATP and increased oxidative stress in 
the cells (Perier et al., 2005). Mitochondrial complex I deficit has been 
identified in several cases of PD (Mizuno et al., 1989, Parker et al., 1989, 
Schapira et al., 1989). Though the cause for the complex I inhibition has not 
been identified, it could be the result of accumulated mutations in 
mitochondrial DNA and deregulation of cellular bioenergetics (Bender et al., 
2006). The PD genes PINK1 and parkin are known to regulate mitochondrial 
function. PINK1 recruits parkin to aid in mitochondrial turnover by autophagy 
(Yu et al., 2011, Vincow et al., 2013). Mutations in these genes lead to 
mitochondrial dysfunction, increased oxidative stress and cell death while 
preventing the autophagy of damaged mitochondria. Increased expression of 
α-synuclein is also known to impair mitochondrial integrity and function 
(Abou-Sleiman et al., 2006). 
1.6.2 Oxidative stress 
Oxidative stress mediated by several factors is a leading cause of cell 
death in PD. The mitochondrial electron transport chain is the major source of 
reactive oxygen species in cells. Inhibition of complex I of the electron 
transport chain leads to increased production of superoxides that can lead to 
oxidative stress in cells (Turrens, 1997, Shiryaeva et al., 2009). In addition, 
reduced expression of antioxidant molecules has been reported in PD. 
Deficiencies in the catalase (Ambani et al., 1975), superoxide dismutase 




(Bellinger et al., 2011) enzyme systems accompanied by a reduction in the 
level of reduced glutathione (GSH) contribute to the increased oxidative stress 
observed in PD (Sian et al., 1994, Thiruchelvam et al., 2005). DJ-1, a PD-
causative gene, is also a known sensor of oxidative stress and exhibits 
antioxidant activity by scavenging hydrogen peroxide (Andres-Mateos et al., 
2007). Mutations in this gene can lead to increased susceptibility to oxidative 
stress (Repici et al., 2013). Another important contributor to oxidative stress is 
dopamine itself. Dopamine is a highly reactive molecule prone to easy 
oxidation. Normally, dopamine is sequestered into synaptic vesicles. However, 
on being oxidized it can react with several cellular components producing 
more toxic ROS (Meiser et al., 2013). Excessive amount of cytosolic 
dopamine is also known to be toxic to neurons (Chen et al., 2008). The 
presence of dopamine is considered an important factor in the susceptibility of 
the SNc dopaminergic neurons to oxidative stress and cell death (Berman and 
Hastings, 1999, Hastings, 2009). In addition to these factors, accumulation of 
iron has been observed in PD (Dexter et al., 1989, Wypijewska et al., 2010). 
Disrupted transferrin-mediated iron transport mechanisms to the mitochondria 
could be the reason for iron accumulation. Iron can react with H2O2 by Fenton 
reaction generating toxic hydroxyl radicals. Hence, increased iron in the SNc 
contributes to increased oxidative stress (Mochizuki and Yasuda, 2012). 
Apart from oxidative stress, nitrosative stress is also observed in PD. 
Increased nitration of α-synuclein tyrosine residues thereby leading to 
increased aggregation (Giasson et al., 2000, Hodara et al., 2004), S-
nitrosylation of parkin (Yao et al., 2004) and protein disulfide isomerase 




processes may all contribute to cell death in PD. Further, nitric oxide reacts 
with ROS to form toxic peroxynitrites. The combined oxidative and 
nitrosative stress can cause neuronal death in PD (Gu et al., 2005, Tsang and 
Chung, 2009). 
1.6.3 Excitotoxicity 
Excitotoxicity via glutamate (Rodriguez et al., 1998, Caudle and 
Zhang, 2009), N-methyl-D-aspartate (NMDA) receptor (Loopuijt and 
Schmidt, 1998, Koutsilieri and Riederer, 2007) and calcium channels (Hurley 
et al., 2013) has been observed in PD. Persistent activation of the NMDA 
receptors and calcium channels leads to increased influx of calcium ions in the 
cells (Surmeier et al., 2011). This increases the activity of endonucleases, 
proteases, phospholipase and nitric oxide synthase producing reactive free 
radicals. It can also impair mitochondrial function and increase lipid 
peroxidation (Jimenez-Jimenez et al., 1996). Thus, excess extracellular 
glutamate initiates excitotoxic cascades that lead to degeneration of 
dopaminergic neurons in the substantia nigra (Beal, 1998, Caudle and Zhang, 
2009). 
1.6.4 Neuroinflammation 
Neuroinflammation is increasingly being recognized as a major 
contributor to the neuronal death in PD (Chung et al., 2010). Sporadic PD 
develops with age and aging is known to cause a persistent low level of 
inflammation in the brain (Pizza et al., 2011). The inflammation mediated by 
the activated microglial cells contributes to increased production of 
proinflammatory cytokines in the brain (Liberatore et al., 1999, Nagatsu et al., 




cells in the substantia nigra region along with increased expression of 
inflammation associated enzymes such as inducible nitric oxide synthase 
(iNOS) (Liberatore et al., 1999) and cyclooxygenase-2 (COX-2) (Teismann et 
al., 2003) in PD patients demonstrated the role of inflammation in the disease 
(Knott et al., 2000). Increased proinflammatory cytokines increase oxidative 
stress and vice versa (Mosley et al., 2006). Hence, a feed-forward cycle of 
inflammation and neuronal death occurs in the pathogenesis of PD (Nagatsu 
and Sawada, 2005, 2006, Ouchi et al., 2009, Litteljohn and Hayley, 2012, 
More et al., 2013).  
 
1.7 Animal models of Parkinson’s disease 
Being a complex, multifactorial disease, a lot of research efforts have 
been invested in the study of the pathogenesis, etiology and molecular 
mechanisms of PD over the past two decades. Experimental animal models 
have been of supreme importance and assistance in obtaining greater insights 
into the disease. Both toxic and genetic models of PD have been used 
extensively as they can effectively replicate many of the features of human 
PD. With the discovery of several PD related genes, the use of genetic models 
in PD studies has increased with the hope that a common mechanism underlies 
the clinical similarities of inherited and sporadic forms of PD. The most 
desirable quality to look out for in these models is the adult onset of specific 
and progressive dopaminergic neurodegeneration. Since rodents are the easiest 
to handle, they are frequently used to model diseases. However, owing to the 
basic differences in organization of the motor system between humans and 




genetic rodent models. Further, approximately only 10% cases of PD are of a 
genetic origin (Klein and Lohmann-Hedrich, 2007) and it is more a 
multifaceted disease. Since the majority of the cases are sporadic, a deeper 
understanding of the functioning of the genetic models is essential. 
Toxin-based models, however, are based on the idea that the selective 
death of dopaminergic neurons occurs by a process that can be caused by a 
variety of signals or insults. The common feature of the toxin-based models is 
the ability of the toxin to induce oxidative stress and specific death of the 
dopaminergic neurons in the substantia nigra (SN) leading to reduction in 
dopamine content like human PD (Dauer and Przedborski, 2003, Bove et al., 
2005). Owing to the ease in developing these toxin-based models compared to 
the genetic ones, they are widely used for PD research in both identification of 
pathogenic mechanisms and in testing neuroprotective strategies. Among the 
neurotoxins, 1-methyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-
hydroxydopamine (6- OHDA) are the most widely used (Schober, 2004). With 
increasing evidence on the role of pesticides in PD, paraquat and rotenone are 
also increasingly being used for animal model generation (Bove et al., 2005). 
Presumably, all these toxins incite the production of reactive oxygen species 
(ROS). MPTP and rotenone can both inhibit the mitochondrial complex I 
though they differ significantly in other aspects (Betarbet et al., 2002, Betarbet 
and Greenamyre, 2007). MPTP is linked to human Parkinsonism and hence is 
the most used compound to model PD. Since the present study employs the 




1.7.1 MPTP model 
MPTP (Fig II) was inadvertently synthesized in place of the narcotic 1-
methyl-4-phenyl-4-propionoxypiperidine (MPPP), an analog of the narcotic 
meperidine and on intravenous administration led to Parkinsonian symptoms 
(Langston et al., 1983). This discovery led to the extensive use of MPTP in 
modeling PD in rodents and non-human primates (Przedborski et al., 2004). 
MPTP is capable of inducing an irreversible Parkinsonian syndrome 
characterized by tremor, rigidity and postural instability in humans and 
monkeys (Przedborski et al., 2000). It also mimics the response to Levodopa 
and other dopamine-replacement strategies similar to human PD (Dauer and 
Przedborski, 2003). Monkeys and mice are considered the best animals for 
MPTP-based PD models as they can replicate the pathological symptoms of 
the human disease (Meredith and Rademacher, 2011, Porras et al., 2012). 
Rats, however, are resistant to degeneration induced by MPTP (Riachi et al., 
1988). MPTP-treated monkeys were widely studied by researchers and were 
found to have selectively lost the dopaminergic neurons in the substantia nigra 
pars compacta sparing the ventral tegmental neurons. Neuromelanin-
containing dopaminergic neurons were especially susceptible to MPTP similar 
to human PD (Herrero et al., 1993). However, the time course of degeneration 
in MPTP-models is quicker compared to PD in humans and the formation of 
Lewy bodies (LBs) has not been widely demonstrated (Forno et al., 1993). 
Further, due to the highly toxic nature of the drug, using it in labs necessitates 
stringent safety measures. Also, different doses and modes of administration 
of MPTP induce different responses in the animals with regards to the 




In spite of these shortcomings, the MPTP-model is the gold standard among 
scientists in studying PD.  
 





On systemic administration, the highly lipophilic MPTP crosses the 
blood-brain barrier and once inside the brain is taken up by the astrocytes 
(Markey et al., 1984). Monoamine oxidase B (MAO-B) present in the 
astrocytes oxidizes the MPTP into its active metabolite MPP+ (Chiba et al., 
1984) which is released into the extracellular space through the OCT-3 
transporter (Cui et al., 2009). The MPP+ molecules have an affinity towards 
the dopamine transporter (DAT) present in the dopaminergic neurons and are 
taken up into the neurons via the transporter (Kitayama et al., 1993, Pifl et al., 
1996). Inside the cells, MPP+ can act in several ways to activate neuronal 




synaptic vesicles (Staal et al., 2000). Since the vesicles have a limited 
capacity, most of the dopamine is pushed into the extracellular space where 
they are metabolized into various compounds, some of which are toxic and are 
subjected to superoxide and hydroxyl radical attacks (Liu et al., 1992). MPP+ 
can also bind to the mitochondrial electron transport chain complex I and 
inhibit oxidative phosphorylation (Nicklas et al., 1987). This leads to the 
depletion of adenosine triphosphate (ATP) thereby harming the dopaminergic 
neurons (Fabre et al., 1999). Blocking the complex I of the mitochondrial 
electron transport chain also increases oxidative stress by the production of 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) both of 
which are toxic to the cells. These events occur very early after the 
administration of MPTP long before the death of the dopaminergic neurons 
indicating that they initiate a cellular death cascade early on (Lee et al., 2000a, 
Abou-Sleiman et al., 2006). Different doses and patterns of MPTP 
administration result in apoptotic or necrotic forms of neuronal death in the 
animals. Low or moderate doses administered over an extended period of time 
induce an apoptotic form of cell death while high doses in a short interval lead 
to an increasingly necrotic form of cell death (Jackson-Lewis et al., 1995). 
Figure III represents the mechanism of action of MPTP. The hallmarks of PD 
produced will hence be a result of the dosing and timing schedules used in 
generating the animal models. Being the best characterized model of PD, 
MPTP-induced PD models are most reliable in studying the mechanisms and 
pathogenesis of PD. The current study employs the MPTP-induced PD mouse 
model based on (Jackson-Lewis and Przedborski, 2007). The model was based 




This acute model was shown to deplete the striatal dopamine levels by 40-90% 
as shown by high performance liquid chromatography (HPLC) and causing a 
prominently non-apoptotic form of cell death. Selection of the strain of mouse 
and the dosage of MPTP to be used are very critical in obtaining a 
reproducible lesion in the mice. The fatality rates vary in the different strains 
of mouse and hence choosing an appropriate dosage for the selected strain 
plays a major role in establishing the model. Further, the gender, sex, age and 
body weight of the mice are major factors in determining the MPTP sensitivity 
and reproducibility of the lesion. The major advantage of using the sub-acute 
model of several injections in a day is that it minimizes prolonged exposure of 
the person to MPTP and that it leads to a stable loss of dopaminergic neurons 
in the SNc after 7 days. However, the mice do not develop parkinsonism and 
show rapid degeneration of neurons unlike the slow death of dopaminergic 






Fig III: Mechanism of action of MPTP.  
On systemic administration, MPTP rapidly crosses the blood–brain barrier and 
is metabolized to 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP
+
) by the 
enzyme monoamine oxidase B (MAO-B) in astrocytes cells, and is oxidized to 




 is taken up by 
dopaminergic neurons by the dopamine transporter (DAT). Inside DA 
neurons, MPP
+
 impairs mitochondrial respiration by inhibiting complex I of 
the electron transport chain. The inhibition of complexI hinders the flow of 
electrons along the mitochondrial electron transport chain, resulting in an 
increased production of free radicals and depletion of ATP which results in 
oxidative stress and activation of cell death pathways (Vila and Przedborski, 
2003) 
 
1.8 Epigenetic mechanisms in PD 
Epigenetics refers to mechanisms which can alter the expression of 
genes without modifying the actual DNA sequence and are heritable (Egger et 
al., 2004).  In spite of having a familial aspect, PD does not show a clear 




variations to the disease state. In this case, an epigenetic framework would be 
most useful in understanding the age-dependence (which is not clearly 
explained by the accumulation of genetic mutations) and the environmental 
impact on genetic predisposition to the disease. A better understanding of the 
complex interplay of genetic and epigenetic factors can help in improving the 
existing knowledge on disease mechanisms and therapeutic strategies. In 
diseases where age and environment play an important role, the identification 
of epigenetic variations contributing to the age and environment mediated 
control of disease mechanism will simplify the disease diagnosis (Bjornsson et 
al., 2004).  Studying epigenetic mechanisms involved in PD can hence be a 
major milestone in the pursuit of understanding the disease better. In recent 
years, the impact of epigenetic mechanisms in PD has been increasingly 
studied (Habibi et al., 2011, Coppede, 2012).  DNA methylation, histone tail 
modifications and microRNA-mediated pathways are considered to play a role 
in the pathogenesis of PD based on recent evidences (Filatova et al., 2012, 
Kaut et al., 2012, Mouradian, 2012, Masliah et al., 2013, Pena-Altamira et al., 
2013). 
1.8.1 DNA methylation 
Methylation of DNA is the most studied epigenetic modification since 
its discovery in cancer in 1983 (Weinhold, 2006). Aging decreases global 
DNA methylation (Christensen et al., 2009, Hernandez et al., 2011) while it 
increases methylation in specific promoters. This could be a contributing 
factor in age-related PD. Methylation of CpG sequences can alter gene 
expression levels by inducing chromatin conformation changes and inhibiting 




al., 2002). Hence, promoter hypermethylation silences gene expression while 
hypomethylation can increase gene expression. Though there have not been 
many reports, there is indication of impaired methylation in PD patients 
(Masliah et al., 2013). SNCA is the gene most studied with respect to 
methylation. Methylation of intron 1 of SNCA gene is associated with 
decreased transcription indicating a role for methylation in the gene expression 
(Jowaed et al., 2010). Decreased methylation of the SNCA gene and reduced 
methylation of SNCA intron 1 has been observed in the SNc of PD patients 
(Matsumoto et al., 2010). It has also been shown that α-synuclein sequesters 
DNA methyltransferase 1 (DNMT1), abundantly expressed in the brain and is 
the important enzyme which maintains DNA methylation, in the cytoplasm. 
Sequestering of DNMT1 in the cytoplasm leads to global hypomethylation in 
PD patients and transgenic PD models. Reduced DNMT1 levels were also 
observed in PD patients and genetic PD models (Desplats et al., 2011). 
Methylation changes were also observed in PARK16/1q32, glycoprotein 
(transmembrane) nmb (GPNMB), and syntaxin 1b (STX1B) genes indicating 
that other PD-related genes could also be prone to methylation changes 
(International Parkinson's Disease Genomics and Wellcome Trust Case 
Control, 2011). However, these modifications have not been clearly linked to 
PD. A recent methylation study on brain and blood samples from PD patients 
has shown that 0.6% of the probes in brain samples and 0.8% of probes in the 
blood samples showed differential methylation of CpG (Masliah et al., 2013). 
Of these, over 80% of the sites were hypomethylated in both blood and brain. 
They also observed a set of genes (major histocompatibility complex, class II, 




(GFPT2), MAPT and vault RNA2-1 (VTRNA2-1)) that are highly associated 
with PD being similarly methylated in brain and blood samples from PD 
patients (Masliah et al., 2013). 
1.8.2 Histone modifications 
The gene expression profiles are also modified by the chromatin state in 
the cells. Chromatin exists as the condensate, inactive heterochromatin state or 
noncondensate, active euchromatin state. Histone protein modifications can 
alter the access of transcriptional machinery to specific promoters leading to 
gene activation or silencing (Cheung et al., 2000). Histone tail modifications 
can occur by acetylation, methylation, phosphorylation, ubiquitylation, 
sumoylation, and other posttranslational modifications (Maze et al., 2013). 
Histone modifications are not well studied in PD patients and most of the 
evidence is obtained from experimental cell culture and animal models of PD. 
Among the PD-related proteins, α-synuclein is known to interact with histones 
and inhibit histone deacetylation (Kontopoulos et al., 2006). Several histone 
deacetylase inhibitors are known to protect against α-synuclein-mediated 
toxicity (Kontopoulos et al., 2006). Inhibition of the histone deacetylase 
sirtuin2 is also known to abate α-synuclein-mediated toxicity and protect 
against dopaminergic neuronal death (Outeiro et al., 2007). Much more work 
regarding histone modifications in PD is required in order to understand the 
mechanism fully. 
1.8.3 MicroRNA 
The epigenetic modifications mediated by the small, non-coding RNAs- 




patients and experimental models. Since the present thesis focus is on miRNA, 
it is reviewed in more detail in the coming sections. 
 
1.9 Overview of microRNAs  
MicroRNAs (miRNAs), discovered in 1993 in Caenorhabditis elegans 
(Lee et al., 1993), constitute an abundant family of small (~ 19-25 nucleotides 
long), non-coding RNAs derived from ~70 nucleotide hairpin pre-miRNA’s, 
constituting about 1-2% of the genes in worms, flies, plants and mammals 
(Bartel, 2009, Ebert and Sharp, 2012). They suppress mRNA expression via 
translation inhibition, degradation or deadenylation of mRNA, thereby  
negatively impacting the protein output (Jackson and Standart, 2007, Pillai et 
al., 2007). Bioinformatic predictions point that each miRNA can target ~200 
genes (Krek et al., 2005) which amounts to a combined regulation of about 
30% of all protein-coding genes (Lewis et al., 2005, Filipowicz et al., 2008). 
miRNAs are shown to play a crucial role in many fundamental biological 
processes like embryonic development, cell proliferation and differentiation 
and metabolism despite their moderate effects on protein expression (Ambros, 
2004, Wienholds et al., 2005, Wurdinger et al., 2008, Gangaraju and Lin, 
2009). Further, the deregulated expression of specific miRNAs has been 
implicated in cancers, heart disorders and neurodegenerative diseases (Volinia 





1.9.1 Biogenesis of microRNAs 
1.9.1.1 miRNA genomics 
The biogenesis of miRNAs seems to be closely related to their 
genomic structure and distribution. Earlier, it was thought that most miRNAs 
are located in intergenic regions with a minority being present in the intronic 
regions leading to the possibility that they are transcribed as autonomous 
transcription units (Kim and Nam, 2006, Kim et al., 2009). However, later 
discoveries revealed that a majority (~70%) of the miRNA genes are located 
in defined transcription units. Based on genomic locations miRNA genes are 
classified as miRNA in the introns of protein coding transcription units, 
miRNA in the introns of noncoding transcription units, and miRNA in the 
exons of noncoding transcription units (Rodriguez et al., 2004). More than 
50% of the miRNA genes are located in close proximity to each other in 
clusters and are transcribed as polycistronic primary transcripts while also 
being under similar regulatory processes (Kim and Nam, 2006, Yuan et al., 
2009). The expression patterns of miRNA are also quite intriguing. Different 
miRNAs exhibit distinct expression patterns specific to developmental stages, 
tissues or cells. A few miRNAs are abundantly expressed in particular cell 
types either owing to robust transcription or due to the slow rate of miRNA 
decay in the cells. 
1.9.1.2 Transcription and processing 
Most miRNA genes are transcribed by the RNA polymerase II (Pol II) 
into primary miRNA transcripts (pri-miRNA), though a small group of them 
are transcribed by Pol III (Kim et al., 2009). The unique features of Pol II 




most pri-miRNA transcripts. Being mostly transcribed by Pol II, the 
transcription process is regulated by several factors in specific conditions and 
cell types (Lee et al., 2004). The Drosha binding/associated proteins, Dicer 
binding proteins, and proteins that bind to the terminal loop of the pri- and/or 
pre-miRNAs are the three main groups of proteins affecting miRNA 
processing. The intergenic miRNA genes are transcribed using their own 
promoters while the intragenic miRNA genes share promoters with their host 
transcripts (Bartel, 2004, Corcoran et al., 2009).  
The pri-miRNA transcripts are several kilobases long and contain one 
to several stem-loop structures (Kim et al., 2009). The first step in the 
processing is the cleavage of the stem-loop to yield the precursor-miRNA 
(pre-miRNA). This cleavage is mediated by the nuclear RNAse III, Drosha 
aided by the DiGeorge syndrome critical region gene 8 (DGCR8) (Lee et al., 
2003). Drosha and DGCR8 form a microprocessor complex which recognizes 
the ~33 base pairs (bp) stem and flanking ssRNA fragments in the pri-miRNA. 
Drosha then cleaves the pri-miRNA strand ~11 bp away from the ssRNA-
dsRNA junction (Han et al., 2006). The cleavage results in a staggered cut 
leaving a 5’ phosphate and a 3’ overhang (Bartel, 2004). One end of the 
miRNA is defined by the Drosha cleavage. This process is called the canonical 
pathway of miRNA processing. The biogenesis and canonical pathway of 
miRNA processing is depicted in Figure IV. Non-canonical pathway of 
miRNA processing occurs in a small group of miRNAs and does not require 
Drosha-mediated processing (Graves and Zeng, 2012). 
The pre-miRNA generated by Drosha/DGCR8 cleavage is exported 




along with the cofactor Ran-GTP (Bohnsack et al., 2004). Exp 5 recognizes 
the dsRNA stem and the short 3’ overhang of the pre-miRNA (Kim, 2004, 
Lund et al., 2004). 
In the cytoplasm, the pre-miRNA is cleaved by the RNAse III endonuclease, 
Dicer, near the terminal loop ~22 nt from the pre-existing pre-miRNA 
terminus. The process releases ~22 nt long miRNA-miRNA* duplexes (Bartel, 
2004).  
The duplex is loaded onto an Argonaute (Ago) protein to form the 
microRNA containing RNA-induced silencing complex (miRISC). One strand 
of the duplex remains attached to the Ago protein as the mature miRNA 
(guide strand) (Bartel, 2004), while the other strand called the passenger 
strand (miRNA*) is degraded (Kim et al., 2009). Depending on the 
thermodynamic stability of the two strands, one will be incorporated into the 
miRISC. In most cases, the strand with relatively unstable base pairs at the 5’ 
end is preferentially integrated into the miRISC (Khvorova et al., 2003, 
Hutvagner, 2005). Strand selection is often not a rigid process and as a result, 
some hairpins are known to produce miRNAs from both strands of the duplex 
at comparable frequencies (Kim et al., 2009).  
Recently, it has been discovered that thermodynamic properties alone 
are not enough to determine the strand choice to be incorporated in the 
miRISC. The steady state abundance of the strand determines whether it is 
called the miRNA or miRNA* (Lau et al., 2001).  It has been shown that in 
some pre-miRNAs both strands are functional miRNAs (Okamura et al., 
2008). If both strands are equally expressed or if the ratio of miRNA:miRNA* 









Fig IV: Biogenesis and transcription of miRNAs. 
Schematic representation of the miRNA biogenesis and canonical transcription 
pathway. The primary miRNA transcript (pri-miRNA) is produced by RNA 
polymerase II or III cleaved by the microprocessor complex Drosha–DGCR8 
(Pasha) in the nucleus. Exportin-5–Ran-GTP exports the resulting precursor 
hairpin, the pre-miRNA to the cytoplasm. In the cytoplasm, the RNase Dicer 
and double-stranded RNA-binding protein TRBP complex cleaves the pre-
miRNA hairpin to ~20nt. The functional strand of the mature miRNA is 
loaded into the RNA-induced silencing complex (RISC) with Argonaute 




silence target mRNAs by mRNA cleavage, translational repression or 
deadenylation (Winter et al., 2009). 
  
1.9.2 Mechanism of action 
miRNAs incorporated into the RISC control gene expression post-
transcriptionally leading to repression of protein output (Filipowicz et al., 
2008). There are currently three known mechanisms by which miRNAs can 
regulate target genes: 1) mRNA cleavage, 2) deadenylation or 3) translational 
repression. The exact mechanism by which a particular miRNA regulates the 
expression of a specific mRNA is however not completely predictable.  
1.9.2.1 Cleavage of target mRNA 
Some miRNAs can mediate endonucleolytic cleavage of their target 
mRNA strands (Yekta et al., 2004, Valencia-Sanchez et al., 2006). However, 
this is possible only when there is full complementarity between the miRNA 
and the target. The formation of an A-form helix between the miRNA and 
target mRNA is essential for the cleavage (Haley and Zamore, 2004). In 
plants, most miRNAs have near perfect complementarity to their targets and 
hence cleave the mRNA strands (Jones-Rhoades et al., 2006) whereas in 
animals cleavage of target mRNA strand by complete complementarity with 
miRNA is quite rare (Brennecke et al., 2005, Brodersen and Voinnet, 2009).  
1.9.2.2 Deadenylation of mRNA 
Inspite of incomplete complementarity, some miRNAs can lead to 
mRNA degradation. These miRNAs mediate degradation by deadenylation 
and decapping of target mRNA strands (Pillai, 2005, Braun et al., 2012). 
Processing bodies (P-bodies) are cytoplasmic structures which play a role in 




family of proteins which are important components of P-bodies are shown to 
interact with the Ago proteins in the RISC and mediate repression of mRNA 
expression (Chekulaeva et al., 2011). GW182 recruits the CAF1:CCR4:NOT1 
deadenylase complex to the target mRNA followed by mRNA decapping by the 
DCP1:DCP2 decapping complex and exonucleolytic degradation of mRNA (Pillai, 
2005, Behm-Ansmant et al., 2006, Piao et al., 2010). The cytoplasmic P-
bodies containing mRNA-degrading enzymes are enriched in Ago proteins, 
mRNA strands and miRNAs indicating that the degradation of deadenylated 
target mRNA strands occurs in these foci (Valencia-Sanchez et al., 2006).  
1.9.2.3 Translational repression 
Translational repression of mRNA targets by miRNAs can occur at the 
initiation and post-initiation stages of protein synthesis as seen from several 
studies. Initiation of translation is prevented by the competitive binding of 
Ago2 and related proteins to the 7-methylguanosine cap of the mRNA thereby 
blocking the binding of eIF4E (Humphreys et al., 2005, Pillai et al., 2005). In 
an alternative mechanism, eIF6, which has a crucial role in the 60S ribosomal 
subunit biogenesis, interacts with the Ago2-Dicer-TRBP complex to prevent 
translation initiation (Chendrimada et al., 2007). Translational repression 
occurring at post-initiation stages is postulated to follow a drop-off model of 
ribosomes leading to premature termination of translation. The association of 
miRNAs and their target mRNA with translationally active polysomes 
supports the post-initiation model of translational repression (Maroney et al., 
2006, Petersen et al., 2006).  
miRNA-mediated repression of protein expression, as postulated by 




accurate understanding of the mechanisms involved with respect to individual 
miRNAs demands much more in-depth research and analysis. 
1.10 Principles of target recognition 
miRNA sequences have an important role in the miRNA-mediated 
gene regulation. The mode of action of the regulation depends on the sequence 
complementarity of the miRNA with target mRNAs. Contiguous base-pairing 
with 5’ nucleotides 2-8 of the miRNA sequence is the essential feature of 
miRNA target recognition (Brennecke et al., 2005). This region is called the 
‘seed region’ of the miRNA. Targets of miRNA are predicted based on the 
complementarity of this seed region to the 3’ UTR sequence of the mRNA 
strands. These target sequences are highly conserved.  Recently, however, 
seed match regions with single mismatches, GU wobbles, insertions or 
deletions have also been shown to be functional targets (Brodersen and 
Voinnet, 2009, Betel et al., 2010). While the degree of complementarity is an 
essential determinant of the mode of regulation of protein expression, the 
target site multiplicity is also an important factor. Existence of multiple 
imperfectly paired target sites on the mRNA for a miRNA can contribute to 
effective translational inhibition (Nielsen et al., 2007).  
Despite the ambiguities in the mode of translational inhibition and the 
presence of multiple target sites for each miRNA, these small RNA molecules 
have been proven to play vital roles in several cellular mechanisms and are of 
great interest to scientists. 
1.11  MicroRNAs in PD 
Several miRNAs have been identified to play a role in PD 




expressed in the brain and are shown to be important regulators of neuronal 
development and maturation and maintenance of the adult nervous system 
(Fiore et al., 2008, Gao, 2010). From studies on knockdown of Dicer in 
embryonic stem cells differentiated into dopaminergic neurons and in adult 
mice, it has been shown that miRNAs are essential for the dopaminergic 
neuronal survival and the loss of miRNAs can be involved in the development 
and progression of PD. This study also identified miR-133b expression to be 
reduced in the midbrain of PD patients unlike control subjects and in mouse 
dopaminergic neuron-deficient models. This miRNA is known to exist in a 
negative feedback loop with pituitary homeobox 3 transcription factor (Pitx3), 
regulating the midbrain dopaminergic neurons terminal differentiation and 
activity (Kim et al., 2007). This was the first study demonstrating the 
importance of miRNAs in PD. Since then, several miRNAs have been proven 















Table 1: List of miRNAs associated with Parkinson’s disease 
MicroRNA Target Reference 
miR-133b Pitx3 (Kim et al., 2007) 
miR-433 Fgf20 (Wang et al., 2008) 
miR-7 α-synuclein  (Junn et al., 2009) 
miR-153 α-synuclein  (Doxakis, 2010) 





α-synuclein, an important protein involved in PD pathogenesis, has 
been shown to be modulated by two miRNAs, miR-7 (Junn et al., 2009) and 
miR-153 (Doxakis, 2010), both enriched in the brain. miR-7 has also been 
shown to be downregulated in MPP+ treated SH-SY5Y cells and MPTP-
treated mice both of which showed increased expression of α-synuclein (Junn 
et al., 2009). The heat shock cognate protein 70 (hsc70) and membrane 
receptor lysosomal-associated membrane protein 2A (LAMP-2A) are 
important proteins in the chaperone-mediated autophagy which helps clear out 
α-synuclein in the cells (Fujiwara et al., 2013). Decrease in the expression of 
these proteins is known to lead to accumulation of α-synuclein. Analysis of the 
SNc in PD patients revealed a decrease in expression of hsc70 and LAMP-2A 




targeting lamp-2a and hsa-miR-26b; hsa-miR-106a*; and hsa-miR-301b 
targeting hsc70. These activities consequently compromise α-synuclein 
degradation leading to its accumulation in the cells (Alvarez-Erviti et al., 
2013). 
LRRK2 gene is known to interact with let-7 and miR-184* from 
studies on Drosophila dopaminergic neurons. Transcription factors E2F1 and 
DP known to control cell cycle and survival are the predicted targets of these 
miRNAs.  Overproduction of these factors is known to negatively implicate 
cell survival. Mutated LRRK2 is known to antagonize the expression of let-7 
and miR-184* leading to increase in expression of E2F1 and DP. 
Supplementing let-7 and miR-184* on the other hand reduces the pathogenic 
effects of LRRK2 mutants. Mutated forms of LRRK2 show an increase in 
kinase activity which is considered the important factor in controlling the 
miRNA expression. The LRRK2 substrate 4E-BP associates with Argonaute 
2, which is the major component of the RNA-induced silencing complex 
(RISC) and this association is promoted by LRRK2 mutants. These mutated 
forms increase the phosphorylation of 4E-BP making it more toxic than the 
wild-type and effectively reduced let-7 expression. Thus, the LRRK2 gene has 
been shown to control the miRNA machinery, though the mechanism is yet to 
be validated on mammalian systems (Gehrke et al., 2010). LRRK2 expression 
also appears to be modulated by miR-205 from studies on the frontal cortex of 
PD patients. The PD patients exhibited relatively low expression of miR-205 
and a high expression of LRRK2. Analysis on the midbrain of normal mice 




al., 2013). However, the pathogenic association of miR-205 and LRRK2 in the 
midbrain of PD patients has not been identified.  
Profiling studies on human post mortem brain tissue identified early 
down-regulation of miR-34b/34c which compromises neuronal viability via 
mitochondrial dysfunction and increased production of ROS. The depletion of 
miR-34b/34c led to a decrease in the expression of DJ-1 and parkin, both 
known to play important roles in mediating cellular response to oxidative 
stress (Minones-Moyano et al., 2011).  
A study on an autosomal recessive model of neurodegeneration has 
demonstrated the increase in expression of miR-132 which can direct the 
decrease in expression of Nurr1. This protein is known to play an important 
role in dopaminergic neuron development and differentiation and its decline 
was accompanied by a decrease in expression of tyrosine hydroxylase in the 
animal model (Lungu et al., 2013). Thus, miR-132 could play a role in the 
dopaminergic neuronal death in PD. 
A miRNA expression profiling study on peripheral blood mononuclear 
cells of PD patients and control subjects has identified 18 miRNAs which aid 
in the clear distinguishing of PD cases and controls. The study identified 3 
miRNAs, miR-30b, miR-30c and miR-26a, associated with the 
glycosphingolipid biosynthesis and the protein ubiquitination pathway known 
to be significant   players in PD pathogenesis (Martins et al., 2011).  
Another study on plasma samples from PD patients and controls 
identified 9 pairs of predictive PD classifiers and 13 differentially expressed 
miRNAs. Extending these results to analyze the plasma from a new set of PD 




1826/miR-450b-3p), miR-626, and miR-505. This result is limited by the fact 
that miRNA changes in plasma can be induced by other factors like 
medications and co-morbidities (Khoo et al., 2012). Further, the exact 
mechanism by which these miRNAs contribute to PD has not been studied.  
Polymorphisms in the 3’ UTR of SNCA gene have been identified in 
genome wide association studies on Asian and Caucasian populations 
indicating that these variants can affect the post-transcriptional machinery 
through miRNA binding sites (Simon-Sanchez et al., 2009, Sotiriou et al., 
2009). Fibroblast growth factor 20 (FGF20), a neurotrophic factor which 
enhances the survival of dopaminergic neurons is expressed preferentially in 
the substantia nigra of the rat brain (Ohmachi et al., 2000). Polymorphic 
variations in the 3’UTR of FGF20 were identified to be linked to PD in a large 
scale study of 644 families (van der Walt et al., 2004). In another study of 729 
families with 1089 affected and 1165 unaffected individuals, a single 
nucleotide polymorphism (SNP) in the 3’UTR binding site for miR-433 was 
identified. Increased FGF20 levels are known to upregulate α-synuclein 
expression contributing to PD pathogenesis (Wang et al., 2008). However, 
detailed analysis on the role of FGF20 polymorphisms has not been carried out 
yet (Itoh and Ohta, 2013).  
 
1.12 Aims of the present study 
As explained in the previous sections, PD is a complex 
neurodegenerative disorder affecting millions of elderly people and becoming 




mechanisms involved in PD is essential for the development of therapeutics 
which can essentially halt neuronal degeneration and potentially cure PD.  
The MPTP-induced PD mouse model has been widely used in studying 
the pathogenic processes involved in dopaminergic neuronal degeneration 
(Meredith and Rademacher, 2011). While there are several different dosage 
regimens used, the acute regimen involving the administration of four 
injections (80mg/kg total dosage) within a day (Jackson-Lewis et al., 1995) 
was adopted for the present study since this is very well characterized. This 
regimen, however, also induced a high rate of death in the mice. 
Hence, the initial phase of the present study was to establish an acute 
MPTP-induced PD mouse model with a total dosage of 72mg/kg in order to 
produce reproducible lesions with reduced fatality in the strain of animals used 
(Jackson-Lewis and Przedborski, 2007). 
1.13.1 To investigate the degeneration of dopaminergic neurons in the 
SNc of MPTP-treated mice 
Dopaminergic neuronal degeneration induced by MPTP has been well studied 
using various dosage regimens (Jackson-Lewis et al., 1995, Tatton and Kish, 
1997, Jakowec and Petzinger, 2004). In order to study the processes and 
mechanisms involved in the degeneration, the following will be carried out: 
 Pathological changes in the SNc will be investigated by Nissl staining 
and tyrosine hydroxylase immunostaining. To analyze the loss of 
neurons in the SNc coronal midbrain sections will be stained using 
cresyl violet stain to visualize the Nissl bodies. TH-immunostaining 
will be utilized to study the loss of TH-immunoreactivity and TH-




 Gene expression of TH and DAT will be assessed at different time 
points after the MPTP treatment to analyze the effect of MPTP on the 
major dopamine signaling genes.  
 Gene expression of proinflammatory cytokines TNFα and IL1β will be 
quantified at different time points after MPTP treatment to prove that 
the procedure induces pathogenic processes similar to PD in the 
animals. Further, the gene expression of iNOS and its 
immunolocalization in the SNc will be studied as its expression is 
increased by proinflammatory cytokines (Koprowski et al., 1993, 
Vitkovic et al., 2000). 
 
1.13.2 To establish an in vitro model of PD using MN9D dopaminergic 
neuronal cell line  
 Using the dopaminergic neuronal cell line MN9D and MPP iodide, an 
in vitro model of PD will be established. MN9D is an immortalized 
embryonic mesencephalic neuronal cell line established by somatic cell 
fusion (Choi et al., 1991). MN9D cells are known to produce dopamine 
and are susceptible to MPP+ treatment and hence used in modeling PD 
in vitro. 
 NeuN and TH immunostaining will be performed on the MN9D cells 





1.13.3 To study miRNA expression changes in the SNc of MPTP-treated 
mice 
MicroRNAs are known to play important roles in several brain-related 
disorders (Lukiw, 2007, Johnson et al., 2008, Skalsky and Cullen, 2011). 
While there have been a few studies on miRNAs in PD (Kim et al., 2007, 
Minones-Moyano et al., 2011), none have focused on the miRNA expression 
changes in the MPTP-induced PD model. Hence, the main aim of the present 
study was to analyze miRNA expression changes in the SNc of the MPTP-
induced PD mouse model. 
 The SNc of MPTP-treated mice and controls from day 5 after MPTP 
treatment will be isolated using Laser capture microdissection (LCM). 
The midbrain coronal sections will be stained using cresyl violet to aid 
in the identification of the dopaminergic neurons and subjected to 
LCM to carefully isolate the SNc dopaminergic neurons with 
minimum contamination of glial cells and other neurons. 
 The isolated tissue will be subjected to miRNA qPCR profiling to 
identify differentially expressed miRNAs in the SNc of MPTP-treated 
mice as compared to controls. 
 Selected miRNAs will be analyzed for expression changes at different 
time points (days 1,3,5,7,10) after MPTP treatment from SNc tissue 





1.13.4 To study the role of miR-124 in MPTP-induced dopaminergic 
neuronal death. 
miR-124 is a brain-enriched miRNA (He and Hannon, 2004), shown to play a 
role in neuronal differentiation during the development of the central nervous 
system and in adult neurogenesis (Lim et al., 2005, Makeyev et al., 2007, Yu 
et al., 2008, Cheng et al., 2009). miR-124 has also been implicated in several 
brain diseases (Pierson et al., 2008, Skalsky and Cullen, 2011, Weng et al., 
2011) and hence the role of miR-124 in the MPTP-induced PD mouse model 
will be investigated. The calpains 1 and 2 which are known to play a role in 
the dopaminergic neuronal death by altering the calpain/cdk5 pathway activity 
(Patrick et al., 1999, Lee et al., 2000b, Crocker et al., 2003, Smith et al., 2006) 
are shown to be modulated by miR-124 expression (Jegga et al., 2011). 
However, the study did not analyze the role on miR-124 in dopaminergic 
neurons or with respect to Parkinson’s disease. Hence, the role of miR-124 in 
modulating the calpain/cdk5 pathway in PD will be assessed. 
 miR-124 expression in the SNc will be obtained from the miRNA 
qPCR profiling. 
 The expression of miR-124 in the SNc of MPTP-treated mice at 
different time points and in the MN9D cells treated with MPP iodide 
will be studied. 
 In situ hybridization analysis of miR-124 expression in MN9D cells 
will be performed. 
 Loss of function studies using miR-124 inhibitors will be done to study 
the effect of miR-124 loss on the calpain/cdk5 pathway. The 




by Western blotting in miR-124 knockdown cells and MPP iodide 
treated cells. ROS/RNS levels and H2O2 levels will also be analyzed. 
The neuronal viability will be measured. 
 Gain of function analysis will be performed by treating MN9D cells 
with MPP iodide. The cells will then be transfected with miR-124 
mimics or negative controls. The expression of calpains 1 and 2, 
p35/p25 and cdk5 will be assessed in the samples by Western blotting. 
Viability of the cells under different experimental conditions will also 
be measured. 
 The miR-124 and calpain 1 target interaction will be studied by 
transfecting miR-124 target site protectors for calpain 1 mRNA in the 
MN9D cells. 
 
1.13.5 To identify PD-associated target genes and pathways of the 
dysregulated miRNAs  
 A PCR array for 84 genes associated with PD will be performed using 
SNc tissue isolated by LCM from MPTP-treated mice on day 5 after 
MPTP treatment. 
 Bioinformatic analysis will be performed using IPA (Ingenuity 
systems) to predict the interactions between the dysregulated miRNAs 




















2.1  Animals  
Adult male C57BL/6J mice aging 8-10 weeks and weighing 20-25g 
were used in generating the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) induced PD model. This particular gender, strain, age and weight of 
animals are the most preferred and reliable for generation of MPTP-induced 
PD models as described by Jackson-Lewis and Przedborski, 2007. A total of 
180 mice were used for the study. All animal experiments were approved by 
and performed complying with the standards set by the Institutional Animal 
Care and Use Committee (IACUC), National University of Singapore. Care 
was taken to minimize animal suffering and the number of animals used in 
experimentation. 
 
2.2 MPTP treatment 
2.2.1 Materials required 
a) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP-
HCl) (Sigma, USA) 
b) 0.9% NaCl  
2.2.2 Injections 
  MPTP-induced PD model was established based on a previously 
described protocol (Jackson-Lewis and Przedborski, 2007). However, since 
the dosage caused acute death of animals around 80-90%, a reduced dosage of 
72 mg/kg was tested. The death of animals at this dosage was observed to be 
20-30% and hence was used for establishing the model. Animals were housed 
in disposable cages with food and water and allowed to acclimatize for at least 




0.9% sterile saline was administered in a series of 4 intraperitoneal injections 
(18mg/kg (free base) in 200µl saline each), adding up to a total dosage of 
72mg/kg, at 2 hour intervals. The control animals were injected an equal 
volume of saline. All injections were performed inside the fume hood with 
necessary safety precautions to prevent personnel from MPTP exposure. The 
MPTP-injected animals were placed on heating pads for an hour after the 
injections to help them recover speedily.  
 The animals were then kept in isolation until the time of sacrifice. 
MPTP-induced animals and time-matched controls were sacrificed at day 1, 3, 
5, 7 and 10 after the last MPTP injection.  
 
2.3 Isolation of brain samples 
2.3.1 Fresh brain samples for RNA isolation 
The mice from days 1,3,5,7 and 10 after the last MPTP injection and 
control animals were anaesthetized with ketamine-medetomidine and 
decapitated. The brains were carefully removed using forceps and washed in 
ice-cold 1X PBS to remove the excess blood. The brains were then snap-
frozen in liquid nitrogen and stored at -80ºC until further processing.  
2.3.2 Perfusion 
Mice from day 7 after the last MPTP injection and time-matched 
control animals were anaesthetized with ketamine-medetomidine. They were 
then perfused with 4% paraformaldehyde and the brains were isolated. The 
samples were post-fixed in 2% paraformaldehyde for 2 hours and then 




overnight, the brain samples were frozen in liquid nitrogen and stored at -80ºC 
until cryosectioning. 
2.4 Isolation of the substantia nigra 
The brains were mounted on cryo-holders and trimmed to the midbrain using 
the coordinates from the mouse brain atlas. Sections of 300µm thickness were 
cut and the overlying cortex and hippocampus are removed. A horizontal cut 
was made just above the pigmented substantia nigra region. The substantia 
nigra was then removed with a vertical cut and stored at -80ºC for further 
RNA or protein isolation. 
 
2.5 Cell culture 
2.5.1 Materials required 
a) Dulbecco's Modified Eagle Medium (DMEM) (Gibco, USA) 
b) Fetal bovine serum (FBS) (Hyclone Thermo scientific, USA) 
c) Trypsin- EDTA (10X, Sigma, USA) 
d) Phosphate buffered saline (PBS) (0.1M, pH 7.4) 
e) 25cm2 cell culture flasks (NUNC Thermo Scientific, USA) 
2.5.2 Cell culture maintenance 
MN9D dopaminergic neuronal cell line obtained from Dr. Alfred 
Heller and Dr. Lisa Won, University of Chicago was cultured in DMEM 
(Gibco, USA) supplemented with 10% FBS (Hyclone Thermo Scientific, 
USA). Cell cultures were maintained at 37º C with 5% CO2.  The media was 
replaced every two days. Once the cells reached 70-80% confluence, the 
cultures were washed with warm PBS-1X and trypsinized with Trypsin-




2.6 MPP iodide treatment 
2.6.1 Materials required 
a) 6-well and 96-well plates (Corning Costar, Sigma, USA) 
b) Sodium butyrate (NaBu) (Sigma, USA) 
c) MPP iodide (Sigma, USA) 
2.6.2 Cell differentiation 
MN9D cells were plated at 2×10
5 
cells per well of 6-well plate or 
3.5×10
3
 cells per well of 96-well plate as per the requirement of the 
experiments. Cells were plated on poly-L-lysine coated coverslips at a density 
of 5×10
4
 cells for immunofluorescence studies and in situ hybridization. 
DMEM (Gibco, USA) supplemented with 10% FBS (Hyclone Thermo 
Scientific, USA) and 1mM sodium butyrate (Sigma, USA) was used to 
differentiate the cells (Choi et al). Media was changed every 2 days and the 
cells were allowed to differentiate for at least 5 days before further 
experimentation. 
2.6.3 MPP+ treatment 
Complete medium from the differentiated cells was replaced by serum-
free DMEM (Gibco, USA) 12 hours prior to MPP iodide treatment. MPP 
iodide (Sigma, USA) was measured inside a fume hood and dissolved in PBS-
1X to obtain a 10mM stock solution. The MPP iodide solution was prepared 
fresh before each experiment. The stock solution was diluted in serum-free 
DMEM (Gibco, USA) to obtain 100 and 200µM concentration. The MPP+ 
containing media was added to the cells and incubated for 24 hours at 37ºC 




2.7 Protein extraction 
2.7.1 Materials required 
a) Mammalian protein extraction reagent (Pierce, USA) 
b) Tissue protein extraction reagent (Pierce, USA) 
c) Protease inhibitor cocktail kit (Pierce, USA) 
2.7.2 Protein extraction 
After the cells were subjected to MPP iodide treatment or transfection, 
the culture media was removed from the 6-well plates and washed with PBS-
1X. 200µl of mammalian protein extraction reagent (Pierce, USA) mixed with 
protease inhibitor and EDTA was added to the cells and left on ice in a shaker 
for 10 min. The cells were then lysed using a cell scraper and the lysate was 
collected in a microcentrifuge tube. For tissue samples, 200µl of tissue protein 
extraction reagent (Pierce, USA) mixed with protease inhibitor and EDTA was 
added and homogenized. Both lysates were centrifuged at 14,000 rpm for 20 
min. The supernatant containing the protein was then collected and stored at -
80ºC until further analysis. 
 
2.8 Estimation of protein concentration 
2.8.1 Materials required 
a) Bovine serum albumin protein standard (BioRad, USA) 
b) Protein assay dye (BioRad, USA) 
2.8.2    Procedure 
The concentration of the protein samples was estimated by the Bradford 
method using bovine serum albumin (BSA) (BioRad, USA) as the standard. 




10µl of each sample or standard were added to a 96- well plate. The protein 
assay dye was diluted 1:5 and 200µl of the dye was added to each well. 
Triplicate reactions for each sample or standard were performed. The plate 
was incubated for 15mins after which the absorbance was measured at 595nm 
using a precision microplate reader (Molecular devices). A standard graph was 
plotted using the absorbance values of the standard solutions with which the 
sample protein concentration was estimated. 
 
2.9 Western Blotting 
2.9.1 Materials Required 
a) 10x Tris/Glycine buffer (BioRad, USA) 
b) 10x Tris/Glycine/SDS (BioRad, USA) 
c) Mini transfer blot filter paper (BioRad, USA) 
d) Polyvinylidene difluoride membrane (BioRad, USA) 
e) Non-fat dry milk powder (BioRad, USA) 
f) Pico chemiluminescent substrate Kit (Pierce, Thermo Scientific, USA) 
g) Stripping buffer (Pierce, Thermo Scientific, USA) 
h) CL-Xposure film- clear blue film (Pierce, Thermo Scientific, USA) 
Equipment 
a) Densitometer with Quantity One software (BioRad, USA) 
b) Electrophoresis Unit (BioRad, USA) 
c) Film developer (Konica Minolta, Singapore) 
d) Gel-casting apparatus (BioRad, USA) 




10% Resolving gel 
a) Water- 4 ml 
b) 30% acrylamide mix- 3.3 ml 
c) 1.5M Tris (pH 8.8)- 2.5 ml 
d) 10% sodium dodecyl sulphate (SDS)- 0.1 ml 
e) 10% ammonium persulphate- 0.1 ml 
f) tetramethylethylenediamine (TEMED)- 0.004 ml 
5% Stacking gel 
a) Water- 5.5 ml 
b) 30% acrylamide mix- 1.3 ml 
c) M Tris (pH 6.8)- 1.0 ml 
d) 10% SDS- 0.08 ml 
e) 10% ammonium persulphate- 0.08 ml 
f) TEMED- 0.008 ml 
6x SDS gel loading buffer 
a) Tris Cl (pH 6.8) 50mM 
b) Dithiothreitol 10mM 
c) SDS 2% 
d) Bromophenol blue 0.1% 
e) Glycerol 10% 
10X Tris buffered saline (TBS) 
a) Tris base- 24.2g 
b) NaCl- 80 g 
Volume made to 1 liter with distilled water 




1X Tris buffered saline tween (TBST) 
a) 10X TBS- 100ml 
b) ddH2O- 900 ml 
c) 10% Tween 20- 10 ml 
The primary and secondary antibodies used are listed in Table 2. 
Table 2: List of primary and secondary antibodies used in Western 
blotting analysis 
Antibodies Commercial source Dilution used 
Primary Antibodies 
Calpain 1 Cell signaling 
technologies 
1:1000 
Calpain 2 Cell signaling 
technologies 
1:500 
p35/p25 Cell signaling 
technologies 
1:500 
Cdk5 Cell signaling 
technologies 
1:1000 




Anti-rabbit HRP BioRad, USA 1:3000 









Samples (40µg protein) were mixed with the 6X loading dye and 
heated at 95ºC for 5mins to denature the proteins. The proteins were separated 
on a 10% SDS-PAGE gel and then electroblotted onto a polyvinylidene 
difluoride (PVDF) membrane (BioRad, USA).  The membranes were then 
blocked using 5% non-fat milk powder in TBST for 1 hour at room 
temperature. After washing the membranes with TBST for 10mins, the 
appropriate primary antibodies diluted in TBST were added. The membranes 
were incubated overnight at 4ºC on a shaker followed by TBST washes (3 
times- 10mins each) the next day. Secondary antibodies conjugated with 
horseradish peroxidase were added to the membranes and incubated for 1 hour 
at room temperature on a shaker. Finally, the membranes were washed twice 
with TBST and once with TBS before adding the chemiluminescence 
substrate. The immunoreactive bands were visualized on X-ray sheets and 
quantified using the Densitometer and Quantity One software (BioRad, USA).  
 
2.10 RNA isolation  
2.10.1 Materials required 
a) miRNeasy mini kit (Qiagen, Germany) 
b) RNeasy micro kit (Qiagen, Germany) 
2.10.2 Procedure 
2.10.2.1 RNA isolation from tissue samples 
Total RNA including microRNA was isolated from the substantia nigra 




manufacturer’s instructions. Briefly, the tissue was homogenized in 700µl of 
QIAzol lysis reagent and vortexed. After 5 min of incubation, 140µl of 
chloroform was added to the homogenate and mixed thoroughly. The 
homogenate was centrifuged for 15min at 12,000×g at 4°C separating the 
solution into three phases. The upper aqueous phase was collected in a tube 
and 1.5 volume of 100% ethanol was added to it. The mixture was thoroughly 
mixed and loaded into an RNeasy mini spin column. After centrifugation, 
RNA binds to the membrane. The column was then washed with RLT buffer 
once and RPE buffer twice to remove phenol and other contaminants. Finally, 
the RNA was eluted in a volume of 30µl RNase-free water. The concentration 
and quality of RNA was checked using the Nanodrop spectrophotometer 
(Thermo Scientific, USA). 
2.10.2.2  RNA isolation from cells 
Total RNA including microRNA was isolated from the cells using the 
miRNeasy mini kit (Qiagen, Germany) following the manufacturer’s 
instructions. 700 µl of QIAzol lysis reagent was added to each well of the 6-
well plate in which cells were differentiated. The cells were lysed using a cell 
scraper and the collected lysate was vortexed to homogenize the cells. The 
remaining steps were followed as in section 2.10.2.1. 
2.10.2.3 RNA isolation from Laser capture microdissected tissue 
RNA for the miRNA qPCR array was isolated using the miRNeasy 
mini kit as described in section 2.10.2.1. RNA for the RT-Profiler PCR-array 
was isolated from the laser capture microdissected tissue using the RNeasy 
micro kit (Qiagen, Germany) following the manufacturer’s instructions. 




vortexing for 30s. An equal volume of 70% ethanol was added to the samples 
and after thorough mixing was transferred to the RNeasy MinElute spin 
column. After centrifugation, the column was washed with buffer RWT 
followed by on-column DNAse digestion for 15min. This was followed by one 
wash with buffer RLT and buffer RPE each. After a final wash with 80% 
ethanol prepared with RNAse-free water, the RNA is eluted in 14µl of 
RNAse-free water. The concentration and quality of RNA was checked using 
the Nanodrop spectrophotometer (Thermo Scientific, USA). 
 
2.11 cDNA synthesis 
2.11.1 Materials required 
Superscript VILO cDNA synthesis kit (Invitrogen, USA) 
2.11.2 Procedure 
Reverse transcription was carried out using 500ng of RNA. Briefly, 
4µl of 5X VILO reaction mix and 2µl of superscript enzyme mix were added 
to 500ng of RNA. The reaction was made up to 20µl with RNAse-free water. 
The mix was incubated at 25°C for 10mins after which the reaction was 
transferred to 42°C for 60mins. The reaction was terminated at 85°C at 5mins. 
The cDNA was stored at -20°C until further use. 
 
2.12 Real time RT-PCR 
2.12.1 Materials required 
a) Fast SYBR green master mix (Applied Biosystems, USA) 




c) MicroAmp Fast optical 96-well reaction plate (Applied Biosystems, 
USA) 
2.12.2 Procedure 
The real time RT-PCR analysis was carried out in the ABi 7900HT 
instrument (Applied Biosystems, USA). Briefly, 5µl of the Fast SYBR green 
master mix (Applied Biosystems, USA), 1µl of forward and reverse primers 
and 3µl nuclease-free water were added to each well of the 96-well reaction 
plate. 1µl of the cDNA (cDNA from the synthesis step diluted with nuclease-
free water 1 in 10 ratio) was added to each well and loaded into the 
instrument. The PCR setting recommended by the manufacturer was used for 
the reaction. Mouse beta-actin primers were used as internal control and the 




2.13 cDNA synthesis for miRNA 
2.13.1 Materials required 
Universal cDNA synthesis kit II (Exiqon, Denmark) 
2.13.2 Procedure 
The total RNA isolated using methods described in section 2.10 was 
diluted to 5ng/µl. A mixture of 2µl of 5X reaction buffer, 4.5µl nuclease-free 
water, 1µl of enzyme mix, 0.5µl of the synthetic RNA spike-in (controls for 
the cDNA conversion and PCR) and 2µl of the RNA (10ng) was prepared. 
The mix was incubated at 42°C for 60mins followed by heat inactivation of 
the reverse transcriptase for 5mins at 95°C. The cDNA was stored at -20° until 




2.14 microRNA PCR 
2.14.1 Materials required 
a) ExiLENT SYBR green master mix (Exiqon, Denmark) 
b) ROX passive reference dye (Promega, USA) 
c) miRNA primers (Exiqon, Denmark) 
2.14.2 Procedure 
The cDNA from step above was diluted 80x in nuclease-free water. 
ROX passive reference dye (Promega, USA) was added to the cDNA samples 
(1µl per 50µL of PCR reaction mix). The real-time PCR reaction was prepared 
by adding 5µl of the PCR master mix, 1µl of primer mix and 4µl of the diluted 
cDNA template. The reaction wass mixed by gentle pipetting and the plate 
was centrifuged at 1500g for 1 minute and loaded into the ABi 7900HT 
instrument. The settings file downloaded from the Exiqon website 
(www.exiqon.com/sds) was used to perform the real-time PCR amplification. 
U6 snRNA (Exiqon, Denmark) was used as reference for the normalization of 
real-time PCR data. 
 
2.15 Cryosectioning 
The mouse brains stored at -80°C were removed and mounted on 
chucks using the cryomounting medium. Coronal sections of the brain at a 
thickness of 20µm were cut and mounted on gelatin-coated slides for 





2.16 Nissl staining (Cresyl-fast violet staining) 
2.16.1 Materials required 
Cresyl Fast Violet stain  
2.16.2 Procedure 
The slides were immersed in a descending series of ethanol 
concentrations and finally in water. They were then immersed in cresyl-fast 
violet stain for 20mins after which they were passed through 70%, 95% and 
100% ethanol and finally two washes of histoclear. The slides were then 
mounted using permount and left to dry. The dopaminergic neurons were 
visualized and imaged using a Nikon light microscope. 
 
2.17 Immunofluorescence and immunohistochemistry studies 
2.17.1 Materials required 
a) Paraformaldehyde (Sigma) – 4% prepared in 0.1M phosphate buffer 
(pH 7.4)  
b) Fluoroshield with DAPI (Sigma, USA) 
c) PBS (10X) (BioRad, USA) 
d) PBS containing 0.1% Triton-X 100 (PBS-TX) 
e) 0.05M Tris buffered saline (TBS; pH 7.6) 
f) 3,3’ diaminobenzidine tetrahydrochloride (DAB) solution 
The primary and secondary antibodies used are listed in Table 3. 
 





Antibody Commercial source Dilution used 
Primary Antibodies 
TH- raised in rabbit Sigma, USA 1:200 
NeuN- raised in 
rabbit 
Santa Cruz, USA 1:100 
iNOS- raised in 
rabbit 
Santa Cruz, USA 1:100 
Secondary Antibodies 
Anti-Rabbit Cy3 Sigma-Aldrich 1:100 
Anti-Rabbit FITC Sigma-Aldrich 1:100 
Anti-Mouse Cy3 Sigma-Aldrich 1:100 
Rabbit IgG Chemicon 1:200 
 
2.17.2 Procedure 
2.17.2.1 Immunofluorescence in vivo 
The cryosections were washed three times in PBS and the endogenous 
peroxide activity was quenched using 0.3% hydrogen peroxide in methanol for 
20 minutes. The sections were rinsed in PBS three times following which they 
were incubated in the primary antibody targeted against TH at 4°C overnight. 
The next day, the sections were washed in PBS three times and incubated with 
the Cy3 conjugated secondary antibody for 1hour at room temperature. The 
slides were then washed three times in PBS and mounted using a fluorescent 




localization was visualized using a confocal microscope (FV1000, Olympus, 
Japan). 
2.17.2.2 Double immunofluorescence labeling in vivo 
The cryosections were stained as in section 2.17.2.1 but using a 
cocktail of primary antibodies against TH and iNOS. After overnight 
incubation with the primary antibodies the sections were washed three times in 
PBS after which they were incubated with the respective FITC/CY3 
conjugated secondary antibodies for 1 hour at room temperature. Thereafter 
the slides were washed and mounted as in section 2.17.2.1. 
2.17.2.3 Immunohistochemistry 
The cryosections were washed with PBS-TX solution three times for 
5min each. The sections were blocked with 5% normal goat serum for 1hour 
after which they were incubated with primary antibody overnight. The 
sections were washed three times for 5min each in PBS-TX. The slides were 
then incubated with biotinylated secondary antibody for 1hour after which 
they were washed three times in PBS for 5min each. The slides were incubated 
with the Avidin-Biotin complex (ABC reagent, Vector Laboratories., USA) 
for 1h. Immunostaining was visualized with 3,3’-diaminobenzidine 
tetrahydrochloride (DAB) as a peroxidase substrate. The sections were 
counterstained with methyl green and dehydrated in graded concentrations of 
ethanol after which they were mounted using permount. The slides were 
visualized under a Nikon light microscope. 
2.17.2.4 Immunofluorescence in vitro 
The differentiated MN9D cells were washed with PBS three times and 




in PBS, the cells were blocked with 5% goat serum for 1hour. The cells were 
then incubated with the primary antibody overnight at 4°C. The next day, after 
three washes of PBS the cells were incubated with the FITC/Cy3 conjugated 
secondary antibody for 1hour at room temperature. The cells were washed 
with PBS three times and then the coverslips were removed and mounted on 
glass slides using a fluorescent mounting medium (Fluoroshield with DAPI, 
Sigma, USA). The cellular localization was visualized using a confocal 
microscope (FV1000, Olympus, Japan). 
 
2.18 In situ hybridization 
2.18.1 Materials required 
a) miRCURY LNA detection probes (5’-fluorescein labelled) - hsa-miR-
124*, U6 control and scramble control (Exiqon, Denmark) 
b) miRCURY LNA microRNA ISH buffer set (Exiqon, Denmark) 
c) 10X PBS (BioRad, USA) 
d) 20X RNAse-free SSC buffer (Ambion, USA) – 5X, 1X and 0.2X SSC 
buffers were prepared and autoclaved. 
2.18.2 Procedure 
1) The 2X microRNA ISH buffer was diluted to 1X with RNAse-free 
water. 
2) Appropriate probe volumes amounting to U6 (1nM final 
concentration), miR-124 (50nM final concentration) and scramble 
(40nM final concentration) were added to RNAse-free tubes and 




3) The tubes were centrifuged briefly to collect the probes at the bottom 
of the tube and 2ml of the 1X-ISH buffer was added to each of the 
tubes. 
4) MN9D cells differentiated on poly-L-lysine coated coverslips were 
fixed with 2% paraformaldehyde for 30mins. 
5) The cells were washed two times in PBS. 
6) The hybridization mix containing the probes (25µl) was added to each 
of the wells and allowed to hybridize at 60°C for 1hour. 
7) The cells were washed in the following series of buffers for 5mins each 
at 60°C. Once in 5X SSC, two times in 1X SSC and two times in 0.2X 
SSC. Finally the cells were washed with 0.2X SSC for 5mins at room 
temperature. 
8) All the washing steps were carried out in the dark. 
9) The coverslips were mounted on glass slides using the fluorescent 
mounting medium with DAPI (Sigma, USA) and visualized using a 
confocal microscope (FV1000, Olympus, Japan). 
 
2.19 Knockdown studies 
2.19.1 Materials required 
a) miRCURY LNA microRNA inhibitors (5’-fluorescein labelled) - hsa-
miR-124 (Exiqon, Denmark) 
b) miRCURY LNA microRNA inhibitor (5’-fluorescein labelled) - 
Negative control A (Exiqon, Denmark) 
c) OptiMEM reduced serum media (Gibco, USA) 





MN9D cells differentiated in 6-well plates were washed with sterile, 
warm 1X PBS two times. The hsa-miR-124 oligos and negative control 
inhibitors (Exiqon, Denmark) at 30µM final concentration were added to 
100µl of OptiMEM media (Gibco, USA). The lipofectamine RNAiMAX 
transfection reagent was added to 100µl of OptiMEM media in a separate 
tube. The media containing the inhibitor and the media with the transfection 
reagent were mixed and incubated at room temperature for 20mins. The mix 
was then added to the cells along with 1.8ml of OptiMEM media. The cells are 
incubated at 37°C with 5% CO2 for 8h and the media was replaced with 10% 
FBS supplemented DMEM. The cells were then returned to incubation at 
37°C with 5% CO2 and after 48h the cells were washed with PBS. Protein was 
extracted from the cells using the mammalian protein extraction reagent 
MPER (Pierce/Thermo Fisher Scientific) for Western blotting analysis. 
MN9D cells differentiated in 96-well plates were transfected with the 
inhibitors following the above procedure and then subjected to cell viability 
assay after 48h of incubation. 
 
2.20 Overexpression studies 
2.20.1 Materials required 
a) mirVANA miR-124 mimics (Ambion, USA) 
b) mirVANA mimic negative control (Ambion, USA) 
2.20.2 Procedure 
MN9D cells differentiated in 6-well plates were treated with MPP 




FBS complete medium. After 1h, the cells were washed with sterile warm 1X-
PBS and then lipofectamine-miR-124 mimic/ lipofectamine-negative control 
mimic complexes were added to the cells. The medium was replaced after 24h 
and the proteins were isolated after 48h for Western blotting analysis. 
 
2.21 Extracellular ROS/RNS and H2O2 assay 
The Oxiselect in vitro ROS/RNS assay kit (Cell Biolabs) was used to 
estimate the amount of ROS/RNS and H2O2 liberated by the miR-124 
knockdown and miR-124 overexpressing cells. The conditioned medium 
obtained from control, miR-124-inhibitor and negative control transfected 
cells was used to measure the total ROS/RNS levels released by these cells. In 
brief, 50μl of sample and DCF standard were added to a 96 well plate. 50 μl of 
catalyst was added to the wells and incubated for 5 min at room temperature. 
This was followed by the addition of 100 μl of DCFH and incubation for 45 
min in the dark at room temperature. The fluorescence of the samples and 
standards was read at 480 nm excitation/530 nm emissions using 
SpectraMaxM5 microplate reader (Molecular Devices). The 2’, 7’-
dichlorodihydrofluorescein standard curve and the hydrogen peroxide standard 
curve generated following manufacturer’s instructions was used to calculate 
the concentration of total ROS/RNS and H2O2 liberated by the cells.  
 
2.22 Cell viability assay 
The cell viability was measured using the Quickcell proliferation kit 
(Abcam, UK) following the manufacturer’s instructions. Briefly, 48h after 




the tetrazolium salt, WST-1 reconstituted in electro-coupling solution was 
added to each well. The 96 well plates were returned to the incubator. Four 
hours later, the optical density was measured at 440 nm using SpectraMaxM5 
microplate reader (Molecular Devices). The cell viability was represented as 
percentage of viable cells as compared to controls. 
 
2.23 Laser Capture Microdissection 
2.23.1 Materials required 
a) Membraneslide 1.0 PEN Nuclease-free (Zeiss, Germany) 
b) Adhesivecap opaque tubes (Zeiss, Germany) 
c) RNAse-free PBS (Ambion, USA) 
2.23.2 Procedure 
Laser capture microdissection (LCM) is a method used to isolate 
highly pure population of cells from a heterogenous tissue section by 
visualization of the cells. LCM was used to isolate the substantia nigra (SN) of 
control and MPTP-injected mice. On day 5 after the last MPTP-injection, 
controls and MPTP-treated mice were anaesthetized using ketamine-
medetomidine. The animals were decapitated and the brains were swiftly 
removed using forceps. After washing in ice-cold RNAse-free PBS, the brains 
were immersed in 30% sucrose prepared in RNAse-free PBS for 3 hours. 
Later, the brains were removed and frozen in liquid nitrogen. The frozen 
samples were stored at -80°C until sectioning. 
The frozen brain samples were mounted on chucks and 10µm coronal 




onto the membrane slides (Zeiss, Germany) and allowed to dry inside the 
cryostat for 2-3mins. The slides were then stored at -80°C until LCM. 
 
2.24 Staining for LCM 
2.24.1 Materials required  
LCM staining kit (Ambion, USA) 
2.24.2 Procedure 
1) Immediately after removing the slides from -80°C, they were washed 
in solutions of 95% ethanol, 75% ethanol and 50% ethanol placed in 
slide chambers for 30s each 
2) The excess ethanol was drained and the edges were marked with a 
Barrier Pen to keep the stain in place. 300µl of the Cresyl Violet stain 
from the LCM staining kit (Ambion, USA) was added on the sections 
and allowed to rest for 1min. 
3) After draining off the excess stain, the slides were washed in the 
following series of solutions placed in different slide chambers: 75% 
ethanol (20s), 95% ethanol (30s), two times in 100% ethanol for 40s 
each, clearene (20s rinse) and finally immersed in clearene for 5min. 
4) The entire procedure was carried out inside a chemical fume hood. 
5) The slides were left to dry for 5mins inside the fume hood after which 
LCM was carried out. 
6) LCM was performed on the PALM MicroBeam Laser Microdissection 
system using the PALM ROBO software (Zeiss, Germany). The 




stain were visualized using the camera attached to the microscope and 
markings were made around the region of interest.  
7) The laser was activated and the tissue pieces were collected on the 
adhesive caps of the Adhesivecap opaque tubes (Zeiss, Germany). At 
least 12 consecutive sections were used for isolation of the SNc tissue. 
8) Immediately after collection, 200µl of lysis buffer (Qiazol for miRNA 
or buffer RLT for mRNA) were added to the tube and incubated upside 
down at room temperature for 5mins.  
9) RNA was isolated from the samples following the steps in section 
2.10.2.3. 
 
2.25 MicroRNA qPCR profiling 
2.25.1 Materials required 
a) Universal cDNA synthesis kit II (Exiqon, Denmark) 
b) miRCURY LNATM Universal RT miRNA PCR Rodent panel I and II 
v2 (Exiqon, Denmark) 
2.25.2 Procedure 
The total RNA isolated as in section 2.10.2.3 (control n=3, MPTP-
treated n=3) using the miRNeasy mini kit was reverse transcribed into cDNA 
in a single reaction step. All microRNAs were polyadenylated in the reaction. 
cDNA and SYBR Green mastermix were transferred to qPCR panels 
preloaded with primers, using a pipetting robot. Amplification was performed 
in a Roche Lightcycler480. Raw Cp values and melting points, as detected by 
the Lightcycler software were exported. Reactions with several melting points, 




and removed from the data set. Reactions with amplification efficiency below 
1.6 and reactions giving Cp values that were within 5 Cp values of the 
negative controls reaction were removed from the dataset. All data were 
normalized to correct for potential overall differences between the samples. 
Normalization was performed based on the average of the assays detected in 
all samples as this is shown to be the best normalization for qPCR studies 
involving numerous assays (Mestdagh, P. et.al.). The formula used to calculate 
the normalized Cp values was:  
Normalized Cp = average Cp (n= 6) – assay Cp (sample)  
A higher value thus indicates that the microRNA is more abundant in the 
particular sample. The control assays were evaluated and unsupervised data 
analysis was performed.  
 
2.26 Mouse Parkinson’s Disease PCR array 
2.26.1 Materials required 
a) RT2 PreAMP cDNA Synthesis Kit (Qiagen, Germany) 
b) RT2 PreAMP Parkinson’s disease Pathway Primer Mix (Qiagen, 
Germany) 
c) RT² Profiler PCR Array (Qiagen, Germany) 
d) RT² qPCR Master Mixes (Qiagen, Germany) 
2.26.2 Procedure 
2.26.2.1 cDNA synthesis and preamplification 
The RNA isolated using the method described in section 2.10.2.3 was 
converted to cDNA following the manufacturer’s instructions. Briefly, 100ng 




free water to make the genomic DNA elimination mix. After incubation at 
42°C for 5min, the mix was placed ice for 1min. To 10µl of the genomic DNA 
elimination mix, 10µl of the reverse transcription mix (5x Buffer BC3-4 μl, 
Control P2-1 μl, cDNA Synthesis Enzyme Mix-1 μl, RNase Inhibitor-1 μl and 
RNase-free water-3 μl) was added and mixed gently. The mix was incubated 
at 42°C for 30min and the reaction was stopped by incubating at 95°C for 
5min. The reaction was placed on ice and 5μl of the mix was added to 12.5 μl 
of RT
2
 PreAMP PCR Mastermix and 7.5 μl of RT2 PreAMP Pathway Primer 
Mix. After gently mixing, the reaction mix was spin down and placed in a 
real-time cycler. The program was set as in the table 4. 
Table 4:Real-time cycler program for cDNA preamplification 
Cycles Duration Temperature 
1 10min 95°C 
12 15s 95°C 
2min 60°C 
Hold  4°C 
 
After the cycle was completed, the reaction mix was placed on ice and 2µ of 
Side Reaction Reducer was added to each sample. After gently mixing, the 
reaction mix was incubated at 37°C for 15 min followed by heat inactivation 
at 95°C for 5 min. 
Immediately afterwards 84 μl nuclease-free water was added and mixed well. 




2.26.2.2 PCR array 
The preamplification mix from the above step (102µl) was added to 
1275µl of 2x RT
2
 SYBR Green Mastermix and 1173µl of RNAse-free water. 
25µl of the mix was pipetted into each well of the PCR array plate and sealed 
with optical adhesive film. The plate was centrifuged at 1000g for 1min. The 
PCR cycling program was set up as in table 5. 
Table 5: RT-PCR program for PCR array 
Cycles Duration Temperature 
1 10min 95°C 
40 15s 95°C 
1min 60°C 
 
A dissociation stage was added to the program for melting curve analysis and 
the program was run in the standard mode. 
 
2.26.2.3 Data analysis 
The CT values were exported to an Excel file and the data were analysed using 
the template from www.SABiosciences.com/pcrarraydataanalysis.php.  
 
2.27 IPA analysis of miRNA profiling data 
The miRNA profile data were analysed using the IPA software 
(Ingenuity® Systems, www.ingenuity.com) to identify target genes and 
pathways. The mRNA expression data from the PD-specific PCR array were 





2.28 Statistical analysis 
The data were represented as Mean±Standard Error of Mean (SEM). 
All analysis was performed using the Graphpad prism software (version 4). 
Statistical significance between groups was calculated using one-way 







































3.1 The acute MPTP-induced PD mouse model 
An acute MPTP-induced PD mouse model was established to aid in the 
investigation of the pathogenic processes in PD. The MPTP-induced mice 
showed symptoms like hunched posture, splayed hind limbs, erect tail 
reaction, hyperactivity and tremor. These symptoms were, however, transient 
and were not observed 24h after the last injection of MPTP. 
  
3.1.1 Neuronal loss 
The present author analyzed the loss of neurons in the substantia nigra 
(SNc) by Cresyl Violet staining (Nissl staining) and tyrosine hydroxylase (TH) 
immunostaining on day 7 after MPTP treatment.  
3.1.1.1 Nissl staining 
The Cresyl Violet stain labels the Nissl bodies in the neuronal 
perikarya. The present author observed a marked decrease in the number of 
dopaminergic neurons in the substantia nigra (SNc) on day7 after the MPTP-
treatment (Fig 1B) as visualized by Nissl staining. There were fewer, darkly 
stained neurons visible in the SNc region after MPTP treatment (Fig 1D). Fig 
1A and 1C show neurons from the control animals.  
3.1.1.2 Tyrosine hydroxylase immunostaining 
Tyrosine hydroxylase (TH) catalyses the rate limiting step in the 
biosynthesis of Dopamine in the brain. In order to analyse the morphological 
changes in the dopaminergic neurons after MPTP treatment, the present author 
performed immunofluorescence studies in the mid-brain sections with anti-TH 
antibody. There was a notable decrease observed in the TH-stained cells in the 




controls (Fig 2A and 2C) on day7 after the MPTP treatment. 
Immunohistochemical analysis revealed the shrunken cell bodies and reduced 
neural fibers in the SNc region of the MPTP-induced mice (Fig 3B and 3D) as 
compared to saline-treated ones (Fig 3A and 3C).  
3.1.2 Tyrosine hydroxylase and dopamine transporter gene expression 
changes 
In order to identify the impact of the acute MPTP treatment on the 
gene expression in the SNc, the expression of tyrosine hydroxylase (TH) and 
dopamine transporter (DAT) genes in the SNc tissue isolated from MPTP-
treated mice and controls on days 1,3,5,7 and 10 after the last MPTP injection 
was analysed by RT-PCR. There was a time-dependent reduction in the 
expression of TH (Fig 4A) and DAT (Fig 4B) genes in the SNc of the MPTP-
treated animals as compared to the saline-injected controls. The decrease in 
expression was not significant on day 1 after the injection. However, from day 
3 to day 10 a significant decrease in the expression of both TH and DAT was 
observed. 
3.1.3 Proinflammatory cytokines in the SNc of MPTP-treated animals 
Neuroinflammation mediated by proinflammatory cytokines is known 
to contribute to neuronal death in PD. Hence, the present author analysed the 
expression of the cytokines TNF-α and IL-1β at different time points after 
MPTP treatment in the SNc of the animals by RT-PCR. A significant increase 
in the expression of both TNF-α and IL-1β was observed one day after the last 
MPTP injection. The expression of the TNF-α remained high until day 3 after 
the MPTP treatment as compared to the controls, after which there was a 




day 5 (Fig 5A). IL-1β expression, however, remained significantly high 
compared to the control until day 5 though it was less compared to the 
expression on day 1 (Fig 5B). 
3.1.4 Inducible nitric oxide synthase (iNOS) expression 
The expression of inducible nitric oxide synthase (iNOS) is a 
consequence of the inflammation resulting from pathogenic processes. The 
expression of the iNOS gene in the SNc of MPTP-treated mice as compared to 
saline-treated controls was analyzed. The mRNA expression of the iNOS gene 
was significantly higher on days 1 and 3 after the MPTP-treatment (Fig 6A). 
From day 5 the iNOS expression was significantly less as compared to days 1 
and 3. Immunofluorescence studies using the iNOS antibody revealed its 
increased expression in the SNc on day 3 after MPTP treatment as compared 
to the controls. Colocalization of iNOS with TH was observed indicating that 
the dopaminergic neurons were also producing an increased amount of the 
enzyme iNOS (Fig 6B). 
 
3.2 MN9D dopaminergic cells 
The MN9D cells were used as an in vitro model of dopaminergic 
neurons. The differentiated MN9D cells had extended processes (Fig 7A). The 
differentiated cells were stained with anti-NeuN antibody to confirm their 
neuronal state (Fig 7B) and were also identified to be dopaminergic by 
immunostaining with anti-TH antibody (Fig 7C). The differentiated MN9D 





3.3 Laser capture microdissection 
Laser capture microdissection was performed on the midbrain coronal 
sections of the animals from day 5 after MPTP treatment to isolate the SNc 
tissue containing mostly the dopaminergic neurons and a minimum possible 
collection of glial cells. Fig 8A shows a section with the SNc tissue 
microdissected. The tissue pieces were collected on the adhesive caps (Fig 8B 
and 8C) and processed for isolation of RNA for the qPCR microRNA and 
mRNA profiling experiments. 
 
3.4 MicroRNA qPCR profiling 
The RNA isolated from the microdissected tissues was subjected to 
microRNA qPCR profiling. Out of the 742 miRNAs assayed, 74 miRNAs 
were differentially expressed between the controls and MPTP-treated samples. 
Among the dysregulated miRNAs, 36 of them were upregulated and 38 of 
them were downregulated (Table 6). A two-way hierarchical clustering 
analysis was performed on 21 significantly changed miRNAs and the heat 
map was generated (Fig 9).  
 
3.5 qPCR analysis of specific miRNAs in the SNc of MPTP-treated 
mice 
From the list of dysregulated miRNAs obtained from the qPCR 
profiling in the LCM SNc samples, the expression of a few significantly 
regulated miRNAs in the SNc of MPTP-treated mice and controls was 




samples did not show much change at different time points the average of the 
control expression values was used for comparison. 
3.5.1 miR-204-5p expression 
When the expression of miR-204-5p was analyzed on days 1,3,5,7 and 
10 after the MPTP treatment, it was found that the expression increased 
significantly compared to controls on day 1. However, the expression 
decreased on day 3 after which there was an increase on day 5 which was 
significant compared to controls. On days 7 and 10, the expression levels were 
reduced as compared to the controls and days 1,3 and 5 (Fig 10A). This 
observation was consistent with the data from the qPCR miRNA profiling on 
day 5. 
3.5.2 miR-129-3p expression 
The expression of miR-129-3p increased significantly on day 1 after 
the MPTP injections. The expression gradually decreased with time though it 
remained significantly high compared to the controls on days 3 and 5. On days 
7 and 10, the miRNA expression was observed to be lesser when compared to 
that of the controls (Fig 10B). 
3.5.3 miR-342-3p expression 
The analysis of miR-342-3p expression on days 1,3,5,7 and 10 
revealed a similar trend as miR-204-5p and miR-129-2-3p. There was a 
significant increase in expression of the miRNA on days 1 and 5 as compared 
to the controls. There was a small dip in expression on day 3 though it was 
higher than the controls and after day 5, the expression remained 




3.5.4 miR-9-5p expression 
The expression of miR-9-5p was found to be increased on day 5 from 
the profiling data. Analysis of the miRNA expression at the different time 
points revealed that the expression of miR-9-5p increased gradually until day 
5 after which the expression decreased rapidly. The expression on day 5 was 
significantly higher as compared to the controls samples (Fig 10D). 
3.5.5 miR-125b-5p expression 
Analysis of miR-125b-5p expression on days 1,3,5,7 and 10 after 
MPTP treatment showed a down-regulation in expression compared to the 
control samples on all the days examined except day 3 when the expression of 
the miRNA was higher compared to the controls (Fig 11A).  
3.5.6 miR-128-3p expression 
The expression of miR-128-3p was found to increase with time from 
day 1 until day 7 as compared to the controls. However, on day 10, the 
expression dropped significantly as compared to day 7 (Fig 11B). 
3.5.7 miR-24-3p expression 
The analysis of miR-24-3p expression revealed an increase in 
expression on days 1 and 3 after MPTP treatment as compared to the control 
mice. However, on day 5 there was a sharp decrease in expression. The miR-
24-3p expression recovered on day 7 but dropped to levels similar to controls 
on day 10 (Fig 11C).  
3.5.8 miR-30b and miR-30c expressions 
The expression of miR-30b and miR-30c on days1,3,5,7 and 10 after 
the MPTP treatment was evaluated. Though the expression of miR-30b was 




the expression was highest on day 1 after which there was a staggered pattern. 
The expression level dropped on day 3 and increased on day 5 after which it 
was reduced on day 7. On day 10, the expression was higher than days3, 5 and 
7 (Fig 11D). 
In the case of miR-30c, the miRNA expression increased on days 1 and 
3 in an ascending manner only to drop significantly on day 5. The expression, 
however, increased significantly on day 7 after which on day 10 it dropped to 
near control levels (11E). 
The expression of all the miRNAs except miR-30c from the qPCR 
analysis were found to correspond to the values from the qPCR array. 
3.6 Role of miR-124 in the MPTP-PD model 
The expression of miR-124 in the substantia nigra of mice treated with 
MPTP was found to be decreased on day 5 post-treatment as compared to 
saline-injected control mice from the LCM sample qPCR miRNA array data. 
The present author wanted to analyse the effect of the loss of expression of 
miR-124, a brain-abundant miRNA, on the death of dopaminergic neurons in 
the MPTP-induced PD model. Hence, a series of experiments were performed 
to identify specific targets of miR-124 which might have an impact on the 
dopaminergic neuronal death in the MPTP-induced PD mouse model. 
3.6.1 miR-124 expression in the MPTP-lesioned mice and MPP+ treated 
MN9D cells 
When compared to control mice, MPTP-treated mice showed a 
significant decrease in the expression of miR-124 after MPTP treatment (Fig 
12A) as observed by RT-PCR at different time points (day 1,3,5,7,10) after 




injections and continued until day 10 where the expression was the lowest. In 
situ hybridization analysis showed the expression of miR-124 in the MN9D 
dopaminergic neurons (Fig 12B). In response to treatment with MPP iodide, 
the expression of miRNA-124 was downregulated in MN9D cells (Fig 12C).  
3.6.2 Calpains 1 and 2- predicted targets of miR-124 
Calpain 1 and 2 which are calcium dependent proteases are known to 
be modulated by miR-124. These proteins are predicted to be targets of miR-
124 by the miRNA target prediction algorithm-Targetscan (version 6.2) (Fig 
13A,B and C) and IPA (Ingenuity systems).The calpains 1 and 2 are reported 
to be involved in the MPTP-induced dopaminergic neuronal death. Hence, the 
effects of miR-124 loss on the expression of calpains 1 and 2 and their 
downstream targets in MPP-iodide treated and miR-124-inhibitor transfected 
MN9D cells were analysed. 
3.6.3 Calpain 1 and calpain 2 expression in MPTP-treated mouse SNc 
The expression of calpains 1 and 2 was found to be significantly 
increased in the SNc of MPTP-treated samples in a time-dependent manner on 
days 3,5,7,10 as compared to the control mice. Immunoreactive bands for 
calpain 1 and calpain 2 both appeared at 80kDa (Fig 14A) and were 
significantly increased in expression as shown in fig 14B and 14C 
respectively. However, the mRNA expression of calpains 1 and 2 did not show 
any significant changes upon MPTP treatment (Fig 14 D and E). 
3.6.4 Transfection of miR-124-inhibitor 
The differentiated MN9D cells were transfected with miR-124 
inhibitors and negative control inhibitors to study the effect of miR-124 loss 




cells are shown in Fig 15. The images were used to confirm the transfection 
efficiency.  
3.6.5 Expression of calpain 1 and calpain 2 in MPP iodide-treated and 
miR-124 knockdown MN9D cells 
Protein expression of calpain 1 showed a significant difference in the 
MPP iodide-treated group and anti-miR-124 transfected group as compared to 
controls. Immunoreactive bands for calpain 1 appeared at 80kDa (Fig 16A) 
and was significantly increased in the MPP iodide-treated group (200µM) and 
the anti-miR-124 transfected group (Fig 16B). The two groups showed similar 
levels of increase in protein expression. The 100µM MPP iodide-treated group 
also showed an increase though not significant as compared to the control 
group.  
Immunoreactive bands for calpain 2 appeared at 80kDa (Fig 16A) and 
showed a significant increase in the MPP iodide-treated (200µM) though not 
in the anti-miR-124 transfected group (Fig 16C).  
3.6.6 Expression of p35 and p25 increased on MPP iodide treatment and 
miR-124 knockdown 
Calpains are known to increase the expression of the cdk5 activator 
p25, which is the cleavage product of p35. Hence, the expression of the p25 
and p35 in the MPP-iodide-treated and miR-124 inhibitor-transfected MN9D 
cells was examined. Western blot analysis showed a significant increase in 
p25 protein expression in both the MPP iodide-treated groups and anti-miR-
124-transfected group. The expression of p25 (immunoreactive band at 
25kDa- Fig 17A) increased with the dose of drug used and was significantly 




group (Fig 17C). The anti-miR-124-transfected group also showed a 
significant increase in p25 expression as compared to the control group with 
the levels being similar to the 200µM MPP iodide-treated group (Fig 17C). 
Immunoreactive bands for p35 at 35kDa (Fig 17A) were found to be slightly 
increased in both MPP iodide-treated groups and the anti-miR-124-transfected 
group as compared to the control group (Fig 17B).  
3.6.7 Increased cdk5 expression 
Both p35 and p25 are known to increase the expression and activity of 
cdk5. Analysing the expression of cdk5 it was observed that the 
immunoreactive band appeared at 30kDa (Fig 18A) and was significantly 
increased in the 200µM MPP iodide-treated group and the anti-miR-124-
transfected group as compared to the control group (Fig 18B).  
The mRNA expression of cdk5 was also significantly increased in the 
anti-miR-124-transfected group as compared to the negative control-
transfected group (Fig 19A) as shown by RT-PCR. 
The MPTP treatment induced an increase in cdk5 mRNA expression as 
compared to control mice in a time-dependent manner as shown by RT-PCR 
analysis of the SNc tissues at different time points after the last MPTP 
injection (Fig 19B). 
3.6.8 Calpain 1 expression increased significantly after miR-124 target 
protector transfection 
In order to identify if the action of miR-124 on calpain 1 was due to 
direct interaction of the miR-124 with the seed region of calpain 1 mRNA 
target protectors which prevent binding of the miR-124 to the calpain 1 




complementary to the seed region of miR-124 and calpain 1 binding site and 
hence competitively bind to the mRNA instead of the miR-124. Transfection 
of miR-124 target protectors for calpain 1 led to an increase in the expression 
of calpain 1 (immunoreactive band at 80kDa) (Fig 20A) as compared to the 
negative control transfected cells as shown by western blotting analysis (Fig 
20B). 
3.6.9 Studies on overexpression of miR-124 in MN9D cells 
In order to analyze if supplementing the MPP iodide treated cells with 
miR-124 could mitigate the expression of calpains, p35, p25 and cdk5, miR-
124 mimics and negative controls were transfected into MN9D cells treated 
with MPP iodide (200µM). Transfection with the negative control mimics into 
the MPP+ treated cells showed similar expression of calpain 1, calpain 2, p35, 
p25 and cdk5 as the MPP iodide-treated cells as demonstrated by Western 
blotting analysis. However, transfection with miR-124 mimics was found to 
mitigate the expression of calpain 1 (Fig 21A), p35 (Fig21C), p25 (Fig 21D) 
and cdk5 (Fig 21E). Calpain 2, however, did not show any significant change 
in expression upon miR-124 overexpression (Fig 21B). The representative 
blots are shown in Fig 21F. 
3.6.10 ROS/RNS and H2O2 production and MN9D cell viability after 
knockdown or overexpression of miR-124 
Increased cdk5 activity is known to increase reactive oxygen species 
(ROS) species and a reduced activity of peroxidase which can lead to 
increased hydrogen peroxide (H2O2) levels. There was a significant (though 
small) increase in extracellular ROS (Fig 22A) and H2O2 (Fig 22B) levels in 




However, transfection of miR-124 mimics did not induce any significant 
changes in the ROS/RNS and H2O2 levels (Fig 22 C and D). While the 
knockdown of miR-124 resulted in a significant reduction in MN9D cell 
viability (Fig 22E), when miR-124 mimics were transfected into MPP+ treated 
MN9D cells it was observed that there was lesser cell death as compared to the 
cells transfected with negative controls and MPP+ treated MN9D cells (Fig 
22F). 
3.7 miRNA target prediction 
The next aim was to identify PD-specific target genes of the 
deregulated miRNAs from the profiling data. In order to identify changes in 
PD-specific genes, a PD specific PCR array was carried out. 
3.7.1 Parkinson’s disease PCR array 
The Parkinson’s disease specific PCR array included 84 genes 
potentially involved in PD pathogenesis. The LCM samples isolated from 
control and MPTP-treated mouse SNc on day 5 after the MPTP treatment were 
subjected to the PCR array to identify the PD-related genes which were 
deregulated in the model. The genes were functionally grouped to represent 
various cellular functions known to be altered in PD. There were 36 
upregulated genes and 20 downregulated genes (Table 7) as observed from the 
PCR array. The 3D profile reveals the fold difference in expression of each 
gene between the control and MPTP-treated LCM samples. Columns pointing 
up (with z-axis values > 1) indicate an up-regulation of gene expression, and 
columns pointing down (with z-axis values < 1) indicate a down-regulation of 





The Scatter Plot graphs the expression level of each gene in the control 
sample versus the MPTP-treated sample. The black line indicates fold changes 
of 1. The pink line indicates 1.5 fold change in gene expression threshold (Fig 
23B). 
The Volcano Plot graphs the log2 of the fold change in each gene's 
expression between the control and treatment samples versus its p value from 
the t-test. The black line indicates fold changes of 1. The pink line indicates 
1.5 fold-change in gene expression threshold and the blue line indicates a p-
value of 0.05 of the t-test threshold (Fig 24). 
3.7.2 PD-specific target mRNAs of the deregulated miRNAs 
The upregulated and downregulated miRNAs from the profiling data 
were subjected to analysis on the IPA to identify potential target genes. The 
expression data from the PD-specific PCR array was added to the miRNA 
target filter. Using expression pairing analysis, inverse expression 
relationships between the miRNA and mRNA were identified. 
3.7.3 Targets of upregulated miRNAs 
The IPA analysis revealed 18 upregulated miRNAs targeting 11 
mRNAs which were downregulated in the PCR array (Fig 25). Performing a 
core analysis on the set of the miRNA and mRNA interactions, an enriched 
network of neurological and psychological disorders, cancer and inflammatory 
response (Fig 26) was seen. Since the focus of the present study was PD, the 
cancer-related molecules were eliminated from the list. The top diseases and 
cellular functions involving the molecules are listed in Table 8. An enrichment 
analysis revealed the top canonical pathways involving the list of miRNAs and 




potential of the mitochondrial membrane and decrease in mitochondrial 
respiration were the top toxicity pathways involving the molecules as revealed 
by the IPA analysis (Fig 28). From the functional network analysis, it was 
noted that these miRNAs and mRNAs are involved majorly in dopamine 
synthesis, retention, translocation and maintenance of dopamine concentration 
along with a few molecules playing roles in dopaminergic cell death (Fig 29). 
3.7.4 Targets of downregulated miRNAs 
The IPA analysis of the downregulated miRNAs and the upregulated 
genes from the PCR array revealed an interaction of 19 miRNAs targeting 23 
mRNAs (Fig 30). A core analysis on the list of molecules obtained showed an 
enrichment of molecules involved in neurological disease, psychological 
disorders, cell death and survival pathways, protein trafficking, cellular 
movement, function and maintenance and cancer (Fig 31). The top diseases 
and cellular functions involving the molecules are listed in Table 9. The major 
canonical pathways in which these molecules function are represented in Fig 
32. Pro-apoptosis and mitochondrial dysfunction are the major toxicity 
pathways which involve the molecules (Fig 33). The increased mRNAs are 
majorly involved in protein catabolism and degradation, loss of neurons, 
axogenesis, migration and function of neurons (Fig 34) as shown by the 
functional network analysis. The various miRNAs linked to the important PD-
related genes and pathways identified from the present study are summarized 

































Parkinson’s disease is the second most common neurodegenerative disorder 
after Alzheimer’s disease (Tanner and Goldman, 1996). With increase in life 
expectancy and improved healthcare facilities, the aged constitute a large 
percentage of the world population. As the population ages the incidence of 
PD has grown immensely in the past few decades, with the numbers 
threatening to further soar in the coming years. PD is postulated to pose a 
major socioeconomic burden by increasing healthcare costs. Being the 
complex, multifactorial disorder it is, several mechanisms have been 
implicated in PD since its discovery. Treatment options which can cure or 
even slow down the progression have also remained elusive due to the limited 
knowledge regarding the exact mechanisms causing the dopaminergic 
neuronal death in PD.  
Animal models have been invaluable in the identification of the 
pathogenic mechanisms in PD and in testing treatment strategies. Among the 
various toxin-induced models of PD, the MPTP-induced PD model has been 
prominently used due to its ability to induce symptoms alike to human PD in 
the animals.  
 
4.1 Pathological changes in the acute MPTP-induced PD mouse 
In the present study, an acute MPTP-induced PD mouse model was 
established adapting previously established protocol with modifications to the 
dosage (72mg/kg) to better suit the experimental conditions and the animals 
used (Jackson-Lewis and Przedborski, 2007). The degenerating neurons were 
demonstrated by Nissl staining and tyrosine hydroxylase immunostaining. 




in the MPTP-treated mice 7 days after treatment, indicating the cell loss 
caused by the MPTP treatment. Tyrosine hydroxylase immunoreactivity has 
been used to quantify the dopaminergic neurons (Zecca et al., 2008) and 
employing immunofluorescence studies using TH antibody, a significant loss 
of TH-immunopositive neurons in the SNc of the MPTP-treated mice was 
observed. Immunohistochemical analysis with the TH antibody showed that 
the dopaminergic fibers were lost due to MPTP treatment. Pathologically, 
these studies demonstrated that treatment with MPTP induced PD-like features 
in the mice. 
 
4.2 MPTP induces TH and DAT gene expression changes 
However, in order to observe changes at the molecular level, the gene 
expression of tyrosine hydroxylase and dopamine transporter in the SNc of 
MPTP-treated mice was analysed. Tyrosine hydroxylase acts as the catalyst 
for the rate-limiting step in the biosynthesis of dopamine and essentially the 
expression level of TH controls the synthesis of dopamine in the SNc (Bisaglia 
et al., 2013). From the gene expression analysis, it was noted that TH 
expression decreases with time in the SNc implicating that the reduction in TH 
contributes to the dopaminergic neuronal loss in the MPTP mice. The 
dopamine transporter is involved in the reuptake of dopamine into the synapse 
and thus plays a critical role in dopaminergic neurotransmission. It also plays 
a major role in MPTP-mediated neurotoxicity as it transports the toxic 
metabolite MPP into the dopaminergic neurons making them susceptible to 
degeneration (Bannon, 2005). The expression of DAT has been found to be 




this feature, the MPTP-induced mice showed a significant decrease in the 
expression of the DAT gene in the SNc proving the association of the DAT 
gene with the loss of dopaminergic neurons in the model. 
 
4.3 Proinflammatory genes are upregulated in the SNc of MPTP-
treated mice 
The involvement of proinflammatory cytokines in mediating the 
neuronal death in PD has been increasingly demonstrated by various studies 
(Chung et al., 2010, Leal et al., 2013). The increased expression of the 
cytokines TNF-α and IL-1β has been reported in PD patients and this increase 
is known to increase the susceptibility of the dopaminergic neurons to death 
(Nagatsu et al., 2000, Nagatsu and Sawada, 2005). Preventing the expression 
of these cytokines is also known to protect dopaminergic neurons. Since PD is 
a result of multiple pathogenic processes, an accurate model of PD should 
replicate at least a few of the mechanisms in human PD. Hence, in the present 
study, the expression of genes involved in inflammatory responses, TNF-α and 
IL-1β in the SNc of MPTP-induced mice was investigated. The expression of 
both genes increasing significantly on the first day after the MPTP treatment 
makes it evident that inflammation contributes considerably to the cell death 
in the SNc. Since activated microglia are the major source of proinflammatory 
cytokines in the brain (Hanisch, 2002), the expression of these genes being 
detected in the SNc tissue is an indication that microglia infiltrate into the 
region  after the MPTP insult. But gradually, the expression of these genes fall 




event in the MPTP-induced PD model but eventually subsides as the neuronal 
degeneration progresses.  
Oxidative stress mediated by reactive oxygen species, especially nitric 
oxide (NO) is considered very critical in MPTP-mediated neurotoxicity (Knott 
et al., 2000). Ablation of the iNOS expression is also known to attenuate 
dopaminergic neuronal death caused by MPTP assault (Liberatore et al., 
1999). Analysing the expression of the inducible nitric oxide synthase (iNOS) 
mRNA in the SNc iterates the role of iNOS in mediating neuronal death as the 
iNOS expression increases significantly one day after MPTP treatment and 
remains high until three days afterwards. However, as the degeneration 
progresses the expression of iNOS returns to basal levels suggesting that the 
increase in iNOS is an immediate after effect of MPTP insult. While the 
activated microglial cells are considered the source of iNOS, the present study 
found that iNOS expression is also colocalized with TH-immunoreactive cells 
indicating that the dopaminergic neurons can produce the enzyme iNOS on 
MPTP insult. Though increased iNOS expression has been reported in the SNc 
of MPTP-induced mice and is known to play a part in inducing the neuronal 
death (Du et al., 2001), there is no evidence of its colocalization with the 
dopaminergic neurons. Hence, the identification that the dopaminergic 
neurons express iNOS is of great interest. However further studies are 
warranted to demonstrate the importance of this finding.  
Thus, the above results demonstrate that MPTP induces pathological 





4.4 MN9D cell line as a model for PD in vitro 
MN9D is an immortalized neuronal hybrid cell line containing 
dopamine produced by the fusion of embryonic rostral mesencephalic 
tegmentum with neuroblastoma cells (N18TG2) (Choi et al., 1991). The 
MN9D cells are a great aid in studying the molecular mechanisms and 
interactions of dopaminergic neurons independent of other neuronal 
populations (Choi et al., 1992). The immunostaining of MN9D cells with 
NeuN antibody shows their neuronal property while their immunoreactivity to 
TH-antibody validates their dopaminergic property. Treating MN9D cells with 
sodium butyrate differentiates them to develop extended processes like 
neurons. MN9D cells treated with MPP iodide has since been widely used as 
an in vitro model of PD. 
 
4.5 Laser capture microdissection helps efficiently isolate the SNc 
region 
Though due care has been taken to isolate the SNc from brain tissue by 
normal dissection methods, the tissue contains a lot of the surrounding glial 
cells. However, employing LCM helped effectively isolates a majority of the 
dopaminergic neurons with minimum glial cell contamination. LCM is a 
difficult technique owing to the fact that the RNA contained in fresh tissue is 
prone to quick degradation and the sectioning, staining and dissection steps 
need to be performed as quickly as possible to obtain RNA that meets the 
quality standards for further experimentation (Espina et al., 2006). After the 
successful isolation of good quality RNA, miRNA profiling and mRNA 




4.6 miRNA expression is modulated in the SNc upon MPTP treatment 
The role of miRNAs in neurodegenerative diseases could be 
multifaceted. They could lead to the accumulation of toxic proteins which is a 
major hallmark of several neurodegenerative diseases or contribute to the 
altered expression of proteins which promote or inhibit cell survival (Eacker et 
al., 2009). Though there have been a few studies focusing on the role of 
individual miRNAs in PD (Harraz et al., 2011), with increasing numbers of 
miRNAs being identified, there is no dearth to the possibilities of finding 
many other miRNAs which might contribute significantly to PD pathogenesis. 
The MPTP-induced PD model is considered the gold standard in studying the 
molecular mechanisms active in the pathogenesis of PD. Several studies have 
identified common mechanisms in action in the MPTP-induced animal models 
and human PD (Bove et al., 2005). Hence, a comprehensive study on the 
miRNA expression changes in the SNc of MPTP-induced mice can provide 
clues about the miRNA changes occurring in the brain of human PD patients. 
The miRNA qPCR profiling data provide evidence that MPTP can induce 
miRNA changes in the SNc. Since miRNAs are increasingly shown to be 
involved in mediating important cellular changes during disease processes, the 
identification of several miRNAs being upregulated/downregulated in the 
MPTP model points out that they are important contributors to the gene 
expression changes occurring in the MPTP model. Since the MPTP-induced 
animal models share several common pathogenic mechanisms with the human 
disease, several (if not all) of these dysregulated miRNAs may be involved in 




4.7 miRNA expressions change with time after MPTP-treatment.  
The miR-204-5p has been studied extensively in various cancers where 
its expression has been reported to be decreased leading to increased migration 
and invasion by the tumor cells (Ying et al., 2013, Zhang et al., 2013a). 
Increased expression of miR-204 was reported in classical macrophage 
activation (Zhang et al., 2013b). Microglia are the resident macrophages of the 
brain and spinal cord and have been found to be activated in the MPTP-
induced Parkinson’s disease models and hence, the increased miR-204-5p 
expression observed in the SNc of the mice after MPTP treatment could be the 
effect of the infiltration of activated microglial cells. 
miR-129-3p has also been studied in the context of cancer, where it has 
been found to be downregulated (Dyrskjøt et al., 2009, Chen et al., 2013, 
Masliah-Planchon et al., 2013). It has also been shown to influence actin 
dynamics to control ciliogenesis (Cao et al., 2012). The important role of miR-
129-3p has been shown to be in cell proliferation by targeting cdk6 (Wu et al., 
2010). However, there are no studies linking this miRNA to brain or PD-
related functions. Since this miRNA increases rapidly on day 1 after MPTP 
treatment, it might have a possible role in the processes leading to 
neurodegeneration, though this needs to be elucidated by careful analysis of 
target genes and further experimentation. 
The expression of miR-342-3p has been shown to be significantly 
upregulated in experimental and idiopathic prion disease and has been 
proposed as a novel marker for prion-induced neurodegeneration (Saba et al., 
2008, Montag et al., 2009). Here in the MPTP-induced PD model, a 




have been mounting for the claim that α-synuclein is a prion-like protein and 
hence PD is a prion-like disorder (Olanow and Brundin, 2013). Identification 
of increased miR-342-3p expression, which is an important marker of prion 
diseases, in the MPTP-induced mice adds support to the prion-like hypothesis. 
However, a careful analysis of miR-342-3p expression in human PD is 
essential to identify if the expression pattern is reflected in human PD. 
miR-9 has been shown to be a potential tumor suppressor as it is 
silenced by aberrant CpG island methylation in several cancers (Lehmann et 
al., 2008, Hildebrandt et al., 2010, Tsai et al., 2011). This miRNA has been 
shown to be downregulated in Huntington’s disease where it exists in a double 
negative feedback loop with the RE1-Silencing Transcription Factor (REST) 
silencing complex (Packer et al., 2008). However, increased miR-9 expression 
corresponds to poor prognosis in glioma (Wu et al., 2013) and the delivery of 
anti-miR-9 to the gliomas has been shown to increase their chemosensitivity 
(Munoz et al., 2013). The expression of miR-9 was found to be increased in 
proinflammatory macrophages and hence considered an important mediator of 
the proinflammatory response of macrophages (Bazzoni et al., 2009). The 
upregulation of miR-9 in the SNc could be the effect of the activated microglia 
which are the CNS macrophages found in the SNc region after the toxic 
MPTP treatment. This idea is strengthened by the fact that miR-9 expression is 
reduced after day 7 when the neuronal loss stabilizes in the MPTP model. 
The miR-125b has been shown to play a role in the differentiation and 
migration of neural stem/progenitor cells (Cui et al., 2012). Expression of the 
miRNA promotes differentiation of the neural stem cells. A study has also 




self-renewing neuroepithelial-like stem cells (lt-NES cells) derived from 
human embryonic stem cells (Stappert et al., 2013). The loss of the miRNA in 
the later stages after MPTP treatment could hence be associated with the 
dopaminergic neuronal loss. This miRNA has also been shown to play a 
proinflammatory role in stroke (Rink and Khanna, 2011) and from the present 
study it is observed that miR-125b is upregulated on day 3 after MPTP 
treatment indicating a possible proinflammatory role for the miR-125b in the 
MPTP model used in the present study.  
The miR-128, known to be involved in neuronal differentiation 
(Papagiannakopoulos et al., 2012), has also been reported to be significantly 
upregulated in the brains of mouse models of prion disease (Saba et al., 2008), 
and Alzheimers’s disease patients (Lukiw, 2007, Tiribuzi et al., 2013). The 
upregulation of this miRNA is also known to disrupt the stability of several 
plasticity-related target genes (Lin et al., 2011). Also, miR-128 level in the 
plasma has been shown to be a highly sensitive biomarker for mild cognitive 
impairment (Sheinerman et al., 2012). Apart from these roles, miR-128 has 
been known to repress nonsense-mediated decay (NMD) which is the process 
which degrades subsets of normal transcripts and aberrant mRNA transcripts 
with premature termination codons (Karam and Wilkinson, 2012). NMD is an 
important post-transcriptional mechanism as ~3-10% of transcripts are 
misregulated when NMD is disrupted (Rehwinkel et al., 2006).  The increased 
expression of miR-128 is known to repress NMD during brain development, 
thereby stabilizing transcripts which will otherwise be degraded by the NMD 
pathway (Bruno et al., 2011). However, in the adult brain, increase in the 




normal functioning of the system by repressing NMD. This could in turn 
modulate the neuronal survival and function. The upregulation of miR-128 
observed in the SNc of MPTP-induced mice in the present study could hence 
play a role in the pathogenic processes by affecting NMD. 
The miR-24 has been shown to be downregulated in in the prefrontal 
cortex of patients with schizophrenia and schizoaffective disorders (Perkins et 
al., 2007). Similarly, the decreased expression of this miRNA was observed in 
the peripheral blood mononuclear cells of aged individuals compared to young 
ones (Noren Hooten et al., 2010). Functionally, miR-24 expression has been 
known to inhibit cell-cycle progression (Lal et al., 2009). In the present study, 
the expression levels are significantly less at later time points after the MPTP 
treatment though it was high in the first few days after MPTP injections. The 
implication of the changes in expression in PD, however, is not very clear. 
The miR-30 family members are known to regulate p53 expression and 
consequently the mitochondrial fission machinery. Increased expression of 
miR-30 family can inhibit the apoptosis resulting from mitochondrial fission 
(Li et al., 2010). In the present study, miR-30b and miR-30c exhibit increased 
expression after MPTP treatment. Increased expression of miR-30b has been 
associated with tumor invasion and immunosuppression in human 
malignancies (Gaziel-Sovran et al., 2011, Shao et al., 2012), while miR-30c 
has been shown to be downregulated in various cancers (Huang et al., 2013, 
Xia et al., 2013). With their contrasting properties, the actual role of miR-30b 





4.8 Effect of miR-124 down-regulation in the dopaminergic neurons 
Considering the fact that miRNAs are stoichiometric inhibitors of 
mRNA translation, the most abundant miRNAs in a particular tissue or cell 
type might be the most pertinent to the biology of the tissue or cell type 
(Eacker et al., 2009). In the present study, expression of miR-124, which is 
abundantly expressed in neurons, was found to be downregulated in a time-
dependent manner in the SNc of MPTP-induced PD mouse model and in 
MN9D dopaminergic neurons treated with MPP iodide. Though miR-124 has 
been implicated in several brain-related diseases (Pierson et al., 2008, Skalsky 
and Cullen, 2011), its role in PD has not been elucidated.   
The reduction in miR-124 was accompanied by the increased 
expression of its target proteins, calpains 1 and 2, which are calcium-
dependent proteases in the SNc of MPTP-treated mice at different time points 
after treatment and in the MPP iodide-treated MN9D cells. The consistent 
activation of calpains has been shown to contribute to dopaminergic neuronal 
death in MPTP-induced PD models and in human PD (Crocker et al., 2003). 
Although miR-124 targets both calpains 1 and 2 (Jegga et al., 2011), down-
regulation of miR-124 in MN9D cells appears to elicit significant increase 
only in calpain 1 expression suggesting a role for miR-124 in controlling the 
expression levels of calpain 1 in these cells. However, the increase in 
expression of calpain 2 was significant in the MPP iodide-treated groups but 
only moderate in the anti-miR-124-transfected groups. As predicted by the 
target prediction algorithm Targetscan (release 6.2), calpain 1 has two 




could be the reason for the higher impact of miR-124 loss on calpain 1 than 
calpain 2. 
In order to analyze if the increase in calpain 1 expression is due to the 
direct interaction of miR-124 with the 3’-UTR of calpain 1, commercially 
available target protector sequences which can interfere with the interaction of 
miR-124 with the calpain 1 mRNA sequence were used. Transfection of the 
target protectors induced an increase in the expression of calpain 1 as shown 
by Western blotting analysis demonstrating the direct interaction of miR-124 
with the calpain 1 mRNA. 
The calpains contribute to dopaminergic neuronal death in human PD 
and MPTP-PD models by increasing the expression and activity of cdk5 (Levy 
et al., 2009). Cdk5 phosphorylates various downstream proteins like myocyte 
enhancer factor 2D (MEF2D) (Smith et al., 2006) and peroxiredoxin2 (Prx2) 
(Qu et al., 2007) which mediate the dopaminergic neuronal death.  
Calpains increase the expression of the stable p25 formed by the 
cleavage of p35, both of which are known to increase cdk5 expression and 
activity (Lee et al., 2000b). In the present study, MPP iodide treatment and 
anti-miR-124 transfection both induced a significant increase in the expression 
of p25. The p25 expression in anti-miR-124-transfected cells was similar to 
the levels in MPP iodide-treated cells suggesting a possible role for miR-124 
in the calpain-mediated cleavage of p35.  
The increased expression of p25 is known to increase cdk5 expression 
and activity (Patrick et al., 1999), and therefore the protein expression of cdk5 
in the MPP iodide-treated and anti-miR-124-transfected MN9D cells was 




increase in cdk5 expression comparable to the increase caused by MPP+ on 
the MN9D cells from the significant increase in cdk5 protein expression 
observed in the anti-miR-124-transfected group as compared to the control 
group of cells. In the SNc of MPTP-induced mice, a time-dependent increase 
in cdk5 mRNA expression was found, as assessed at different time points 
starting at 24h after the last MPTP injection up to 10 days after MPTP 
treatment, as compared to control mice. Increase in cdk5 activity is known to 
increase reactive oxygen species (ROS) production (Qu et al., 2007, Sun et al., 
2008) and transfection of anti-miR-124 oligos in MN9D cells induced a 
significant increase in ROS production as compared to controls. The 
transfection of miR-124 inhibitors in MN9D cells induced a significant 
increase in total ROS/RNS production as compared to controls implying that 
the reduction of miR-124 can increase oxidative stress in the cells. Further, an 
increase in hydrogen peroxide levels was also observed on knockdown of 
miR-124 in the MN9D cells. Deregulated cdk5 can inactivate peroxiredoxins, 
which scavenge hydrogen peroxide and ROS, thereby leading to oxidative 
stress-mediated mitochondrial dysfunction and neuronal death. Since damaged 
mitochondria elevate the expression of ROS, a vicious cycle of cellular 
damage is activated. From the experimental observations, miR-124 appears to 
contribute to the increased oxidative stress. However, further studies are 
warranted to analyze if the reduction in miR-124 can induce changes in the 
expression of mitochondrial component proteins leading to the dysfunction of 
mitochondria in the MPTP model.  
In order to better understand the function of miR-124 in the MPP 




MPP iodide-treated MN9D cells. A significant decrease in the expression of 
calpain 1, p35, p25 and cdk5 was observed in the miR-124-transfected cells as 
compared to the negative control-transfected cells indicating that 
supplementing miR-124 could mitigate the expression of these proteins after 
MPP+ treatment. In addition, the viability of the cells overexpressing miR-124 
was higher than that of negative controls suggesting that miR-124 can help in 
the survival of the MN9D cells after MPP iodide treatment. However, the 
levels of ROS/RNS and H2O2 did not show much change in both groups. 
There is a high basal expression of miR-124 expression in the MN9D cells and 
overexpression of miR-124 in the normal MN9D cells might not be of 
relevance since PD is a disease where there is a significant loss of neuronal 
viability by the time it is diagnosed. Hence, the approach of overexpressing 
miR-124 in the MPP iodide treated cells to mimic the diseased state was 
adopted. 
While the present study demonstrates a role for miR-124 in the 
calpain/cdk5 pathway mediated dopaminergic neuronal death, additional 
studies are warranted to identify the molecular events that lead to its reduction 
in the MPTP-treated animals and MPP iodide-treated cells. An in-depth 
analysis of the mechanisms involved in the control of miR-124 will provide 
the strategy to manipulate it for therapeutic purposes. 
miRNA expression changes are evident in the SNc of MPTP-treated 
mice as compared to the control animals from the present study. Nevertheless, 
the significance of these changes in the pathogenic processes in the MPTP 
model can be evaluated only on the basis of their ability to induce changes in 




transcriptional stage thereby modulating the protein production. However, 
identifying mRNA networks modulated by the miRNAs can aid in 
understanding the impact of the miRNA expression changes. Each miRNA 
can target thousands of mRNAs thereby providing an extensive list of mRNA 
targets clouding the process of identifying the genes of significance in the 
present study. Since the main focus of the present study is PD, employing a 
PD-specific PCR array which profiles genes highly implicated in PD, 
narrowed down the gene targets for analysis.  
Since miRNAs act by suppressing the expression of the target mRNA 
or protein, depending on the complementarity with the seed region of the 
mRNA, the analysis was done based on expression pairing. The analysis 
revealed several important miRNAs regulating the PD-related genes. 
 
4.9 Pathways and genes modulated by upregulated miRNAs 
Among the upregulated miRNAs, 18 of them target 11 of the 
downregulated mRNAs from the PCR array. Considering that each of the 10 
mRNAs are targets of more than one miRNA that are dysregulated in the 
MPTP model it is possible that the expression of these genes in PD is 
significantly controlled by miRNAs.  
4.9.1 Dopamine signaling pathway 
Dopamine, though synthesized by only a small group of neurons in the 
brain (which are projected widely in the telencephalon) has been widely 
implicated in learning, memory, movement and motivation (Chinta and 
Andersen, 2005). The importance of dopamine is reiterated by the fact that 




addiction and schizophrenia. The major PD symptoms arise from the loss of 
dopamine producing neurons in the SNc. Dopamine is produced from the 
amino acid L-tyrosine by its conversion to L-DOPA (L-3,4-
dihydroxyphenylalanine), which is the precursor of dopamine, catalysed by 
the enzyme tyrosine hydroxylase (TH). Dopamine is synthesized from L-
DOPA by the enzyme DOPA decarboxylase (DDC) (Bisaglia et al., 2013). 
The highly reactive dopamine is sequestered in synaptic vesicles by the 
vesicular monoamine trasnsporter 2 (VMAT2) (Eiden et al., 2004). Once it is 
released into the synaptic cleft, dopamine exerts its actions through the 
dopamine receptors. However, dopamine transporter (DAT) acts to rapidly 
reuptake dopamine into the presynaptic terminals (Chen and Reith, 2000) 
since excess dopamine in the extracellular space is toxic to the cells due to its 
rapid oxidation (Chen et al., 2008).  
Several genes involved in the dopamine signaling pathway are altered 
in PD. These include TH, VMAT2 and DAT. Since TH catalyses the rate-
limiting step in the biosynthesis of dopamine, a decrease in TH expression and 
activity leads to failure in dopamine synthesis which could represent an early 
pathological event in PD. The toxin MPTP is also capable of inducing a 
decrease in TH expression similar to human PD, hence replicating a 
significant pathogenic event in the onset of PD (Ara et al., 1998). Analysis of 
the miRNA and mRNA expressions predicts that the miR-34a-5p (which is 
upregulated in the SNc of the MPTP mice) targets TH. The miR-34a has so far 
been implicated in several cancers where it functions as a tumor suppressor 
(Bommer et al., 2007, Liu et al., 2011). The expression of miR-34a has also 




apoptosis while knocking down its expression using antagomirs has been 
shown to be neuroprotective (Hu et al., 2012). The expression of miR-34a was 
also found to be increased in a transgenic model of Alzheimer’s disease where 
it downregulated the expression of Bcl2 (Wang et al., 2009). Given that the 
miR-34a has been implicated in other models of neuronal death, the present 
study suggests that it could also play a role in the dopaminergic neuronal death 
in PD.  
VMAT2 belonging to a solute carrier protein family is responsible for 
maintaining the cytosolic concentration of dopamine by packaging them into 
vesicles (Eiden et al., 2004). It acts as an antiporter preventing the 
accumulation of dopamine after synthesis or reuptake. Considering that the 
oxidation of dopamine is highly toxic to neurons, decrease in expression or 
activity of VMAT2 is essentially detrimental to the neuronal survival. In aid of 
this concept is the fact that gain-of-function haplotypes in the VMAT2 
promoter have a protective role for PD in women (Glatt et al., 2006). VMAT2 
has been shown to be targeted by the upregulated miRNA, miR-9-5p from the 
present study in the MPTP-induced animals. Considering the importance of 
VMAT2 in the pathogenesis of PD, the miR-9-5p interaction with the mRNA 
is of high significance as it provides the option for modulating the miRNA to 
alter the expression of the gene in an attempt to regain VMAT2 expression in 
PD.  
The reuptake of dopamine once released into the extracellular space is 
very critical in the dopamine-mediated neurotransmission. DAT plays a 
substantial role in the process of reuptake thereby regulating the intensity and 




of action for toxins like MPTP (Javitch et al., 1985) and paraquat (Sanchez-
Ramos et al., 1987) which bind to DAT preventing the transport of dopamine 
back into the presynaptic neuron. These toxins are transported into the 
dopaminergic neurons through DAT where they accumulate and cause damage 
by inhibiting mitochondrial function and increasing oxidative stress. The 
present study has revealed that DAT is targeted by miR-30b-5p, miR-34a-5p 
and miR-532-3p all of which are upregulated in the SNc of MPTP-treated 
mice.  
The present study has brought into focus miRNA interactions with 
important genes of the dopamine signaling pathway which have not been 
implicated in PD earlier. 
4.9.2 miRNAs targeting LRRK2 
The LRRK2 gene has been linked to PD owing to the reports of its 
mutations in familial and sporadic PD. The expression level of LRRK2 mRNA 
in the SNc has been contentious as some studies have reported that the SNc 
lacks LRRK2 mRNA expression (Melrose et al., 2006) while others claim a 
high expression level of the mRNA in the SNc (Simón-Sánchez et al., 2006, 
Higashi et al., 2007, Han et al., 2008). The present study, however, shows that 
LRRK2 mRNA is downregulated in the MPTP-treated mouse SNc as 
compared to the controls. So far only one miRNA, miR-205, has been shown 
to interact with LRRK2 (Cho et al., 2013). The expression of miR-205 was 
significantly decreased in the frontal cortex of PD patients while there was an 
increase in the LRRK2 protein expression. Further, the expression of miR-205 
has been shown to suppress LRRK2 protein expression by binding to the 




been shown to antagonize the expression of miRNAs, let-7 and miR-184* 
(Gehrke et al., 2010). This has proven the ability of LRRK2 to regulate the 
miRNA machinery. The analysis results from the present study link the 
expression of miR-103-3p and miR-9-5p to the expression of LRRK2 mRNA 
in the SNc of MPTP-induced mice. While the expression of mutated forms of 
LRRK2 is the major change attributed to PD (Healy et al., 2008, Cookson, 
2012) its function in the normal physiological state is not yet clear though it 
plays a role in mitochondrial function and dynamics (Giasson et al., 2006) . A 
modification in its kinase activity due to mutations is known to regulate 
mitochondrial function which is known to be impaired in PD. However, the 
reduced expression of LRRK2 is known to induce dopaminergic neuronal 
death and reduced TH expression from studies on neural progenitor cells 
(Milosevic et al., 2009). Further reduction in LRRK2 expression is known to 
increase the sensitivity of cells to dopamine (Roth and Eichhorn, 2013). 
Hence, the reduction in LRRK2 mRNA observed in the MPTP-induced SNc 
could be of significance in the dopaminergic neuronal death occurring in the 
model. Considering the fact that miRNAs lead to down-regulation of mRNA 
expression, the role of miR-103-3p and miR-9-5p in controlling LRRK2 
expression is highly significant though further investigation is needed to 
understand their influence on initiating the pathogenic processes in PD. 
4.9.3 α-synuclein and miRNAs 
α-synuclein (SNCA) is a major component of Lewy bodies found in 
PD and mutations in SNCA have a high penetrance and are a leading cause of 
familial PD (Polymeropoulos et al., 1997, Ross et al., 2008). Increased 




PD. The mRNA expression of SNCA in PD, however, has been controversial. 
While a few studies have reported increase in SNCA mRNA in the SNc 
(Chiba-Falek et al., 2006), many others have shown a down-regulation of 
SNCA mRNA in PD patients (Kingsbury et al., 2004, Papapetropoulos et al., 
2007). In the present study, there was a significant down-regulation of SNCA 
mRNA in the SNc of MPTP-treated mice as compared to controls. There were 
4 miRNAs (miR-34a-5p, miR-342-3p, miR-495-3p and miR-7b-5p) which 
were predicted to target SNCA mRNA and were upregulated in the SNc of the 
MPTP-induced animals. Among these, miR-7 has been proven to control the 
expression of SNCA (Junn et al., 2009, Doxakis, 2010). The other 3 miRNAs 
identified are novel regulators of SNCA expression identified from the present 
study and might be of relevance in the α-synuclein pathology in PD.  
4.9.4 GABAB receptor 2 and miRNAs 
Another significant finding from the present study was the down-
regulation of the gamma-aminobutyric acid receptor 2 (GABBR2). It is a 
subunit of the GABAB receptor and is required along with the Gamma-
aminobutyric acid receptor 1 (GABBR1) for the normal functioning of the 
receptor. The GABAB receptor is associated with K+/Ca2+ channels, linked to 
G-proteins and produces slow inhibitory signals (Nakayasu et al., 1995, Pinard 
et al., 2010). Functionally the GABAB receptors modulate the release of 
neurotransmitters including dopamine, serotonin, noradrenaline, somatostatin, 
glutamate and GABA (Fatemi et al., 2011). Changes in GABAB receptors 
have been reported in autism, bipolar disorders, depression and schizophrenia 
(Ishikawa et al., 2005, Fatemi et al., 2009, Sequeira et al., 2009). Defective 




al., 2012). Reduced GABBR2 expression in the SNc of MPTP-induced mice 
implicates the dysfunction of GABBR2 in PD. It was found that several of the 
upregulated miRNAs (let-7b-5p, miR-101a-3p, miR-93-5p, miR-204-5p, miR-
34a-5p, miR-495-3p and miR-9-5p) are predicted to target the GABBR2 
mRNA indicating that the GABAergic transmission is highly regulated by 
miRNAs in the MPTP model. This essentially implies that the GABA 
receptors are highly inhibited in the SNc of MPTP-induced mice disrupting 
their inhibitory action on neurotransmission.  
From the present study, it has been observed that the upregulated 
miRNAs in the SNc of MPTP-induced PD mice act to downregulate mRNAs 
which are mainly involved in dopamine signaling, GABA receptor signaling, 
mitochondrial function and 14-3-3-mediated signaling. The major toxic effects 
of the down-regulation of the miRNA-targeted mRNAs, involves pathways 
that decrease the respiration and transmembrane potential of mitochondria 
leading to mitochondrial dysfunction which is highly implicated in PD. These 
results suggest the importance of the upregulated miRNAs in regulating the 
dopaminergic neuronal death in the MPTP model of PD. 
 
4.10 Pathways and genes modulated by the downregulated miRNAs 
Among the downregulated miRNAs, 21 were predicted to target 40 
upregulated mRNAs from the present PCR array analysis.   
The molecular functions of a majority of the upregulated mRNAs were 
in cell to cell signaling and interactions, cell death, morphology and cellular 




dysfunction are the other important pathways where several of the target 
mRNAs play a role. 
4.10.1 Mitochondrial dysfunction 
PINK1 and Park7, both highly implicated in PD since mutations in 
these genes cause familial PD, are upregulated in the MPTP-induced mouse 
SNc. Pink1 plays an important role in maintaining mitochondrial respiration 
and health and in mitophagy (Yu et al., 2011, Matsuda et al., 2013, Vincow et 
al., 2013). The present study predicts an interaction of miR-124-3p and miR-
598-3p with PINK1 mRNA. Park7 or DJ-1 is an important mediator of 
oxidative stress in the cells (Im et al., 2012). Upon oxidative insult, DJ-1 
mRNA expression is known to increase, implying that it has a role in the 
cellular defense mechanism against oxidative stress (Lev et al., 2008, Baulac 
et al., 2009). From the present study, miR-128-3p and miR-544-3p are 
predicted to target Park7 mRNA. Further analysis of the miRNA interactions 
of these two genes could provide valuable information regarding modulation 
of their expression for therapeutic purposes. 
Optic Atrophy 1 (Opa1) is a dynamin-related GTPase in the inner 
mitochondrial membrane which plays a role in mitochondrial fusion and pro-
apoptotic mitochondrial remodelling (Ramonet et al., 2013). Overexpression 
of Opa1 is known to induce mitochondrial elongation and affects transport 
while also controlling the release of cytochrome c from the mitochondria. In 
the MPTP-induced SNc, there was an increase in Opa1 corresponding with a 
down-regulation of the miRNAs targeting Opa1 (miR-128-3p, miR-27a-3p).   
Caspase7 and caspase 8 (the former an effector caspase and the latter an 




increased in their expression in the MPTP-treated mouse SNc. Both these 
caspases are known to play important roles in apoptotic cell death, implicating 
an apoptotic mechanism of cell death in the MPTP-model. miR-125a-5p, miR-
23a-3p and miR-29b-3p (which are downregulated in the MPTP model) are 
predicted to target caspase 7 from the present study. Caspase 8 was predicted 
to be targeted by miR-128-3p in the present study. 
The results of the present study have brought into focus several 
miRNAs targeting genes involved in mitochondrial function which can be 
exploited to understand the dysfunction of mitochondria in PD. 
4.10.2 Protein ubiquitination 
The ubiquitin–proteasome system (UPS) is an important non-
lysosomal protein degradation pathway in cells. The system is responsible for 
degradation of misfolded intracellular proteins by regulating protein turnover. 
Besides, the UPS also plays a role in several cellular mechanisms like 
survival, stress response, apoptosis and intracellular signaling (Ciechanover, 
1998). The UPS is known to be dysregulated in sporadic and familial PD (Yao 
et al., 2004, Gu et al., 2005).The present study has revealed the interactions of 
several miRNAs with genes in the UPS. These include the ubiquitin-
conjugating enzyme E2K (Ube2k) which is targeted by miR-128-3p, miR-23a-
3p, miR-24-3p, miR-27a-3p, miR-29a-3p and miR-328-3p, ubiquitin-
conjugating enzyme E2L3 (Ube2l3) targeted by miR-125a-5p and miR-544-3p 
and the poly(A) specific ribonuclease subunit homolog (S. cerevisiae) (Pan2) 
which is targeted by miR-1249-3p, miR-125a-5p and miR-29a-3p.  These 
interactions signify that miRNAs are important regulators of the ubiquitination 




The brain-derived neurotrophic factor (BDNF) expression was found 
to be upregulated in the SNc of MPTP-induced mice from the PCR array. 
BDNF was shown to be targeted by several miRNAs which include miR-124-
3p, miR-26a-5p and miR-328-3p.  
The upregulated miRNAs reveal an important regulation that exists in 
controlling mitochondrial dysfunction and ubiquitination in the MPTP-
induced PD model. The interactive network of the miRNAs and target mRNAs 
are shown to be implicated in pro-apoptotic and mitochondrial dysfunction 
pathways mediating toxicity in the dopaminergic neurons.  
The present results suggest that the injection of MPTP induces changes 
in several miRNAs which could precede the gene expression changes 
observed in the model. The present results bring to light a complex miRNA-
mediated regulatory network in the MPTP-induced dopaminergic neuronal 
death. Most miRNAs exert their influences at the protein level without 
modulating mRNA expression. But, an inverse relationship between miRNA 
expression and their corresponding target mRNA expression suggests the 
importance of the miRNAs in inducing changes even at the mRNA level. 
Hence, these interactions are novel and noteworthy and can be explored 
further at the protein level. The identification of specific miRNAs targeting 
important genes in the PD pathogenesis is an important step in developing 



























The pathogenesis of Parkinson’s disease (PD) has been studied extensively for 
several decades; however, the molecular mechanisms underlying the 
pathogenesis are not completely understood. Numerous new molecular signals 
with an impact on dopaminergic neuronal degeneration are being unveiled 
with time. The microRNAs (miRNAs) play a significant role in the regulation 
of gene expression in cells. Despite being only ~20 nucleotides long, they 
regulate several cellular processes in normal and diseased states. Based on the 
hypothesis that miRNAs play an essential role in the gene expression changes 
in the MPTP-induced PD model the present study was focused on identifying 
miRNA changes that play roles in PD-related genes and pathway regulation. 
The present study has utilized the acute MPTP-induced mouse model of PD to 
analyze the expression changes of miRNAs in the substantia nigra pars 
compacta (SNc) upon MPTP treatment. The SNc was isolated by laser capture 
microdissection 5 days after MPTP treatment in order to isolate the 
dopaminergic neurons of the SNc with minimum contamination from glial 
cells. A qPCR profiling of miRNA expression revealed that several miRNAs 
were dysregulated in the SNc after MPTP treatment. A parallel qPCR array for 
84 genes implicated in PD was performed to understand the impact of miRNA 
dysregulation on PD-specific gene expression changes. The analysis of the 
combined miRNA and mRNA expressions has brought into light several 
interactions between miRNAs and genes known to play a part in PD 
pathogenesis. The miRNAs with increased expression targeted genes involved 




functioning and some important PD-specific genes like LRRK2 and SNCA. 
Down-regulation of the genes involved in dopamine signaling and 
mitochondrial function is a major hallmark of PD and identification of 
miRNAs which regulate these pathways is an important outcome which can be 
manipulated to achieve therapeutic benefits. Some novel miRNA interactions 
which were previously not reported have been uncovered from the present 
analysis. LRRK2 was shown to be targeted by miR-103-3p and miR-9-5p and 
SNCA was targeted by miR-34a-5p, miR-342-3p and miR-495-3p. These 
interactions are worth pondering over and can be studied in detail to analyze if 
they are similarly regulated in human PD.  
The miRNAs with a decrease in expression have been shown to target 
several genes involved in mitochondrial dysfunction and protein 
ubiquitination. These two processes are significantly altered in PD and are 
responsible for dopaminergic neuronal death. The association of miRNAs with 
these genes provides clues to the mechanisms involved in their regulation and 
can be utilized to identify novel therapeutic targets or biomarkers. PINK1 and 
DJ-1 (both important genes implicated in PD) were shown to be targeted by 
miRNAs which were not studied previously. PINK1 was targeted by miR-124-
3p and miR-598-3p, while DJ-1 was targeted by miR-128-3p and miR-544-3p. 
None of these interactions have been reported in other studies and hence could 
be suitable choices for further study. 
Among the dysregulated miRNAs, the brain-enriched miR-124 was 
significantly downregulated in the SNc of MPTP-induced PD mice. The 
decreased expression of miR-124 was found to target calpain 1 as shown by 




protectors. Though both calpains 1 and 2 were upregulated in MN9D 
dopaminergic neuronal cells treated with MPP iodide, only calpain 1 protein 
expression was increased in miR-124 knockdown MN9D cells. With increase 
in calpain 1 expression, there was increased expression of p25, a cleavage 
product of p35, which activates cdk5. There was an increased expression of 
cdk5 resulting from increased p25 expression. Prolonged expression and 
activity of the cdk5/p25 complex is known to be toxic to the neuronal cells, as 
depicted by the decreased viability of MN9D cells upon miR-124 knockdown. 
This was accompanied by a marginal but significant increase in ROS/RNS and 
H2O2 in the miR-124 inhibitor-transfected cells. These results suggest an 
important role for miR-124 in the dopaminergic neuronal death in PD through 
the increased expression of the calpain 1/cdk5 pathway proteins. MN9D cells 
treated with MPP iodide and then transfected with miR-124 mimics showed a 
reduction in the expression of the calpain 1/cdk5 pathway proteins along with 
an increased cell viability compared to the MPP treated cells and MPP treated 
+ negative control transfected cells. These results suggest an important role for 
miR-124 in the survival of dopaminergic neurons and Fig V shows the miR-





Fig V: Illustration of miR-124-mediated modulation of calpain 1/cdk5 
pathway. 
 
In conclusion, the results provide an insight into the changes induced in 
overall miRNA expression in the SNc of MPTP-treated animals which 
regulate several important genes and pathways implicated in PD. These results 
could pave way for the development of a range of miRNA-based PD 
therapeutics by supplementing lost miRNAs or inhibiting overexpressed 
miRNAs which can result in altering the pathogenic gene expression changes 




Currently there are only a few limited studies on miRNA changes in PD and 




expression. The present study provides promising miRNA candidates for 
verification and study in other animal models and human PD. The remarkable 
similarity of the pathogenic mechanisms in the MPTP-induced animal models 
to PD makes it plausible to study similar miRNA changes in humans. Novel 
miRNA-mRNA interactions will provide strategies for the development of 
potential therapeutics for PD in the future.    
From the present study, miR-124 has been shown to play a role in the 
degeneration of dopaminergic neurons. To identify its role in vivo, miR-124 
inhibitors can be injected in the brain of mice to identify the effect of the loss 
of miR-124 expression on the survival of dopaminergic neurons. 
Further, supplementing the miR-124 in the MPTP-induced mouse SNc using 
mimics or miR-124 overexpressing-mesenchymal stem cells can help to study 
if there is reversal or halting of dopaminergic neuronal degeneration in the 
mice.  
The acceleration of miRNA-related discoveries unravels a new path 
towards biomarker identification and development of miRNA-based 
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Fig 1. Photomicrographs showing Nissl staining of control (A and C) and 
MPTP-treated (B and D) SNc on day 7 after MPTP treatment. There is a 
reduction in the number of neurons and they appear shrunken on treatment 










                
        
 
Fig 2. Confocal images showing dopaminergic neurons in the SNc marked by 
TH in the control (A and C) and MPTP-treated (B and D) in the SNc on day 7 
after MPTP treatment. There is a visible reduction in the number of TH-









Fig 3. Light microscopic images showing the loss of TH-fibers in the SNc 
after MPTP treatment (B and D) on day 7 as compared to the controls (A and 
C). The number of TH-positive cells on day 7 after MPTP treatment. Each bar 









Fig 4. A) TH gene expression in the SNc as compared to controls on days 
1,3,5,7,10 after MPTP treatment, B) DAT gene expression in the SNc as 
compared to controls on days 1,3,5,7,10 after MPTP treatment. Each bar 
represents mean±SEM. * represents statistical significance p< 0.05 and ** 









Fig 5.A) TNF-α gene expression in the SNc as compared to controls  on days 
1,3,5,7,10 after MPTP treatment, B) IL-1β gene expression in the SNc as 
compared to controls on days 1,3,5,7,10 after MPTP treatment. Each bar 
represents mean±SEM. * represents statistical significance p< 0.05 and ** 












Fig 6. A) iNOS gene expression in the SNc as compared to controls on days 
1,3,5,7,10 after MPTP treatment. Each bar represents mean±SEM. * 
represents statistical significance p< 0.05 and ** represents p< 0.01 (One-way 
ANOVA, n=5), B) Confocal images showing TH and iNOS staining in the 











Fig 7. A) Image of differentiated MN9D cells, B) Confocal images of MN9D 
cells stained with neuronal marker NeuN, C) Confocal images of MN9D cells 













Fig 8. A) Light microscopic images showing the SNc after removal by Laser 
capture microdissection (LCM), B) and C) Tissue collected on the adhesive 













Fig 9. Heat map generated by two-way hierarchical clustering analysis of 
significantly differentially expressed microRNAs in the SNc of MPTP-treated 
animals isolated by LCM on day 5 after treatment. C represents the control 











Fig 10. Expression of A) miR-204, B) miR-129-3p, C) miR-342-3p, D) miR-
9-5p in the SNc as compared to controls on days 1,3,5,7,10 after MPTP 
treatment. Each bar represents mean±SEM. * represents statistical significance 
















Fig 11. Expression of A) miR-125b-5p, B) miR-128-3p, C) miR-24-3p, D) 
miR-30b and E) miR-30c in the SNc as compared to controls on days 
1,3,5,7,10 after MPTP treatment. Each bar represents mean±SEM. * 














Fig 12. A) miR-124 expression in SNc as compared to controls on days 
1,3,5,7,10 after MPTP treatment, B) in situ hybridization images of MN9D 
cells showing miR-124 expression, C) miR-124 expression in MN9D cells 
after 24 hours of MPP+ exposure at 100 and 200µM. Each bar represents 




















Fig 13. Target interaction of miR-124 with 3’UTR of A), B) calpain 1 and C) 
















Fig 14. Western blot showing the protein expression of calpain 1 and calpain 2 
in SNc of MPTP-treated mice with controls at days 3,5,7 and 10 after MPTP 
treatment, A) Immunoreactive bands of calpain 1 (80 kDa), calpain 2 (80 kDa) 
and beta actin (42 kDa), B) Bar graph showing the fold changes in calpain 1 
expression in each group as compared to controls C) Bar graph showing the 
fold changes in calpain 2 expression in each group as compared to control. D) 
and E) Bar graphs showing the relative mRNA expression of calpain 1 and 
calpain 2 at different time points after MPTP treatment as compared to 
control. Each bar represents mean±SEM. * represents statistical significance 
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Fig 15. Images of fluorescent miR-124 inhibitor transfected MN9D cells to 































Fig 16. Western blot showing the protein expression of calpain 1 and calpain 2 
in MPP+ treated and anti-miR-124 transfected MN9D cells with controls, A) 
Immunoreactive bands of calpain 1 (80 kDa), calpain 2 (80 kDa) and beta 
actin (42 kDa), B) Bar graph showing the fold changes in calpain 1 expression 
in each group as compared to controls C) Bar graph showing the fold changes 
in calpain 2 expression in each group as compared to control. Each bar 
represents mean±SEM. * represents statistical significance p< 0.05 and ** 












Fig 17. Western blot showing the protein expression of p35 and p25 in MPP+ 
treated and anti-miR-124-transfected MN9D cells as compared to controls, A) 
Immunoreactive bands of p35 (35 kDa), p25 (25 kDa) and beta actin (42 kDa), 
B) Bar graph showing the fold changes in p35 expression in each group as 
compared to control, C) Bar graph showing the fold changes in p25 expression 
in each group as compared to control. Each bar represents mean±SEM. * 









                                                                                                                                                                                                











Fig 18. Western blot showing the protein expression of cdk5 in MPP+ treated 
and anti-miR-124 transfected MN9D cells with controls, A) Immunoreactive 
bands of cdk5 (30 kDa) and beta actin (42 kDa), B) Bar graph showing the 
fold changes in cdk5 expression in each group as compared to controls. Each 
bar represents mean±SEM. * represents statistical significance p< 0.05 (One-


































Fig 19. A) mRNA expression of cdk5 in anti-miR-124-transfected MN9D 
cells as compared to the negative control, B) mRNA expression of cdk5 in 
control and MPTP-treated mice on days 1,3,5,7,10 after treatment. Each bar 
represents mean±SEM. * represents statistical significance p< 0.05 and ** 


















Fig 20. Western blot showing the protein expression of calpain 1 after 
transfection of miR-124 target protectors A) Bar graph showing the fold 
changes in calpain 1 expression as compared to the negative control, B) 
Immunoreactive bands of calpain 1 (80 kDa) and beta actin (42 kDa). 






























Fig 21. Western blot showing the protein expression of calpain 1, calpain 2, 
p35, p25 and cdk5 in the MPP iodide-treated MN9D cells which are 
transfected with miR-124 mimics and negative controls. Bar graph showing 
the fold changes in expression of A) calpain 1, B) calpain 2, C) p35, D) p25 
and E) cdk5. F) Immunoreactive bands of calpain 1 (80 kDa), calpain 2 
(80kDa), p35 (35kDa), p25 (25kDa), cdk5 (30kDa) and beta actin (42kDa). 










































                                                                             
 
 
                    



















Fig 22. A) ROS/RNS production in anti-miR-124 transfected MN9D cells as 
compared to negative control transfected cells and B) H2O2 production in anti-
miR-124 transfected MN9D cells as compared to negative control transfected 
cells measured in RFU, C) ROS/RNS production in miR-124-mimics 
transfected MN9D cells as compared to negative control transfected cells and 
D) H2O2 production in miR-124-mimics transfected MN9D cells as compared 
to negative control transfected cells measured in RFU, E) Neuronal cell 
viability in the miR-124 knockdown cells and F) MPP+ treated MN9D cells 
transfected with miR-124 and control mimics expressed as a percentage of 
control. Statistical significance is represented by * p< 0.05 and ** p< 0.01 









Fig 23 A) 3D Profile of fold difference in expression of each gene between the 
control and MPTP-treated LCM samples. Columns pointing up (with z-axis 
values > 1) indicate an up-regulation of gene expression, and columns 
pointing down (with z-axis values < 1) indicate a down-regulation of gene 
expression in the MPTP-treated samples relative to the control sample, B) 
Scatter Plot of the expression level of each gene in the control sample versus 
the MPTP-treated sample. The black line indicates fold changes and the pink 











Fig 24. Volcano Plot of the log2 of the fold change in each gene's expression 
between the control and treatment samples versus its p value from the t-test. 
The black line indicates fold changes of 1, and the pink line indicates 1.5 fold-
change in gene expression threshold and the blue line indicates a p-value of 


























    





                      
  








                                 
Fig 26. Core analysis of the upregulated miRNAs and downregulated mRNAs in the SNc of MPTP-treated mice on day 5 after MPTP treatment revealing enriched interaction networks involving the miRNAs and 













































     
Fig 27. Top canonical pathways involving the upregulated miRNAs and 


















Fig 28. Major toxic processes initiated by the upregulated miRNA and 













          








                                                                          
















     
Fig 31. Core analysis of the downregulated miRNAs and upregulated mRNAs in the SNc of MPTP-treated mice on day 5 after MPTP treatment revealing enriched interaction networks involving the miRNAs and 












Fig 32. Top canonical pathways involving the downregulated miRNAs and 







Fig 33. Major toxic processes initiated by the downregulated miRNA and 








                                           











































Table 6: Dysregulated miRNAs in the SNc of MPTP-treated mice 
identified by qPCR profiling 



















































Table 7: Dysregulated mRNAs in the SNc of MPTP-treated mice 
identified by qPCR profiling 











































Table 8: List of top diseases and cellular functions involving the 
upregulated miRNAs and downregulated mRNAs identified by IPA 
analysis 
Diseases and Disorders 
 
Name p-value # Molecules 
 
Neurological Disease 5.77E-18 - 5.00E-03 23 
 
Psychological Disorders 5.77E-18 - 5.00E-03 22 
 
Cancer 4.87E-12 - 5.00E-03 25 
 
Reproductive System Disease 4.87E-12 - 5.00E-03 18 
 
Hematological Disease 4.61E-11 - 3.02E-03 12 
 
Molecular and Cellular Functions 
 
Name p-value # Molecules 
 
Cell-To-Cell Signaling and 
Interaction 
8.62E-09 - 5.00E-03 12 
 
Drug Metabolism 8.62E-09 - 3.34E-03 8 
 




8.62E-09 - 5.00E-03 9 
 















Table 9: List of top diseases and cellular functions involving the 
downregulated miRNAs and upregulated mRNAs identified by IPA 
analysis 
Diseases and Disorders 
 
Name p-value # Molecules 
 
Cancer 1.40E-15 - 5.30E-03 32 
 
Neurological Disease 2.13E-14 - 5.96E-03 30 
 
Psychological Disorders 2.13E-14 - 5.96E-03 28 
 
Hereditary Disorder 4.13E-12 - 4.72E-03 22 
 











Molecular and Cellular Functions 
 
Name p-value # Molecules 
 
Cell-To-Cell Signaling and 
Interaction 
4.43E-09 - 6.20E-03 11 
 
Molecular Transport 2.57E-07 - 4.72E-03 8 
 
Small Molecule Biochemistry 2.57E-07 - 4.72E-03 10 
 
Cell Death and Survival 2.96E-07 - 5.30E-03 22 
 
Cell Morphology 7.20E-07 - 6.34E-03 16 
 
